Document:

<PAGE>   1
                                                                   Exhibit 10.29

                          PATENT AND TECHNOLOGY LICENSE
                                       AND
                          REGISTRATION RIGHTS AGREEMENT

        This PATENT AND TECHNOLOGY LICENSE AND REGISTRATION RIGHTS AGREEMENT
(this "Agreement") is made as of March 29, 2000 by and between AccuMed
International, Inc., a Delaware corporation ("AccuMed"), and BCAM International,
Inc., a New York corporation ("Licensee").

        NOW, THEREFORE, for valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, AccuMed and Licensee hereby agree as follows:

                                    SECTION 1
                                   DEFINITIONS

        The following capitalized terms used in this Agreement shall have the
respective meanings ascribed to them below in this Section unless otherwise
expressly defined in this Agreement (such definitions shall be equally
applicable to both the singular and plural forms of the defined terms). The
words "hereof," "herein" and "hereunder" and words of like import when used in
this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement, and Section references are to this
Agreement unless otherwise specified.

               "AccuMed Improvement" means any redesign, enhancement, or
modification, of the Licensed Products, whether or not patentable, developed by
AccuMed or any third party on AccuMed's behalf.

               "Affiliate" means, with respect to a specified Person, (a) any
Person that directly or indirectly controls, is directly or indirectly
controlled by, or is directly or indirectly under common control with such
specified Person.

               "Cash/Stock Payment" has the meaning set forth in Section 3.3.

               "Claim" means a patent claim made in a pending patent application
or in an issued patent.

               "Copyrighted Work" means AccuMed's copyrighted works which relate
to the Patent Rights or Technology and which are delivered to and accepted by
Licensee pursuant to Section 2.7.

               "Field" means the field of morphological, cytochemical,
cytogenetic, and

<PAGE>   2

quantitative sputum cytology, including without limitation DNA,
malignancy-associated changes, and any other genetic or molecular diagnostic
analyses for early lung cancer detection, screening, diagnosis, prognosis and
therapeutic monitoring.

               "Field Exclusivity" means that the Field is exclusive to
Licensee.

               "Foreign Patents" means, collectively, the letters patent, if
any, covering Claims of the U. S. Patents which are applied for by AccuMed or
issued to AccuMed in a country other than the United States as listed on
Schedule 2 (as amended from time to time to include all future AccuMed patents
related to the Field), subject to the provisions of Section 5.1 governing the
prosecution thereof.

               "Guaranteed Cash License Fee" has the meaning set forth in
Section 3.1.

               "Licensed Product" means any device, apparatus, instrument,
equipment, consumables, data, system, or component thereof, or method or process
or embodiments thereof which are covered by the Claims of the Patents or the
subject matter of the Technology, including without limitation AcCell, TracCell,
MACcell, AcCell-Savant, AccuTech, BioSight, Cognetics (certain of the preceding
product names are trademarks of AccuMed), DNA stains and kits, and related
supplies (e.g. calibration slides).

               "Licensee Improvement" means any redesign, enhancement, or
modification, of the Licensed Products, whether or not patentable, developed by
Licensee or any third party on Licensee's behalf.

               "Non-Cancellation Period" has the meaning set forth in Section
9.3.

               "Patents" means, collectively, the U. S. Patents and the Foreign
Patents.

               "Person" means any individual, sole proprietorship, partnership,
limited liability partnership, joint venture, trust, unincorporated
organization, association, corporation, limited liability company, governmental
authority, or any other entity.

               "Proprietary Information" has the meaning set forth in Section
6.1.

               "Required Royalty" has the meaning set forth in Section 3.2.

               "Sales" means the gross amount of all sales, revenues, receipts,
cash, monies, fees, other amounts invoiced or collected by Licensee (whether on
its own or through its distributors or agents) in any currency or denominations
(whether in cash or by way of other benefit, advantage, or concession (in which
case the applicable revenue will be the monetary equivalent or value of same))
from the manufacture, use, sale, offer to sell, rental, lease or other transfer
of any Licensed Product, including without limitation on a per click, per test,
per assay, per slide or per use basis.

               "Stock Payment" has the meaning set forth in Section 3.4.

                                       2
<PAGE>   3

               "Technology" means product designs, models, prototypes,
schematics, copyrighted works, know-how, technical information, and trade
secrets (including, without limitation, ideas, formulas, compositions,
inventions (whether patentable or unpatentable and whether or not reduced to
practice), manufacturing and production processes and techniques, research and
development information, drawings, blue prints, specifications, designs, bills
of material, computer software, and documentation), and embodiments thereof (in
whatever form or medium) of AccuMed (whether currently existing or developed by
AccuMed during the term of this Agreement) which directly relate to the Field,
and to, more generally, computer-aided microscopy, quantitative microscopy
systems, and automated cytometry and histomery systems..

               "Termination Default" has the meaning set forth in Section 8.1.

               "Territory" means the United States and any other country
throughout the world.

               "U. S. Patents" means (i) Patents and the Applications for
Letters Patent listed on Schedule 2 (as amended from time to time to include all
future AccuMed patents related to the Field), (ii) the continuations,
continuations-in-part or divisions thereof, (iii) the letters patent issuing
therefrom by the United States Patent and Trademark Office, and (iv) the
extensions, renewals or reissues of such letters patent.

                                    SECTION 2
                        LICENSE OF PATENTS AND TECHNOLOGY

        2.1 GRANT OF LICENSE IN PATENTS. AccuMed hereby grants to Licensee, and
Licensee accepts from AccuMed, a non-transferable, non-divisible license to
make, have made, use, offer to sell, and sell Licensed Products covered by the
Claims of the Patents (whether now existing or developed in the future by
AccuMed) throughout the Territory on the terms and provisions hereof; the
license is exclusive as to the Field.

        2.2 GRANT OF LICENSE IN TECHNOLOGY. AccuMed hereby grants to Licensee,
and Licensee accepts from AccuMed, an exclusive, non-transferable, non-divisible
license to make, have made, use, offer to sell, and sell Licensed Products
covered by the subject matter of the Technology (whether now existing or
developed in the future by AccuMed) throughout the Territory on the terms and
provisions hereof; the license is exclusive as to the Field.

        2.3 GRANT OF LICENSE IN COPYRIGHTS. AccuMed hereby grants to Licensee,
and Licensee accepts from AccuMed, an exclusive, nontransferable, non-divisible
license to use and copy the Copyrighted Works in the Field on the terms and
provisions hereof.

        2.4 SCOPE OF GRANT. (a) The licenses in the Patents, the Technology, and
the Copyrighted Works granted hereunder are not transferable (except as
expressly permitted by Section 11.8) and no right to sublicense is extended by
this Agreement. Licensee acknowledges that no license or right is hereby granted
by implication, estoppel, or otherwise, under any patent or patent right,
know-how, or trade secret not expressly identified in this Agreement. Licensee

                                       3
<PAGE>   4

shall not make, have made, use, offer to sell, sell, or otherwise commercially
exploit any Licensed Products outside the scope of the licenses granted
hereunder.

               (b) AccuMed reserves all rights not expressly granted herein. The
license in the Copyrighted Works granted hereunder shall be coincident and
coterminous with the licenses in the Patents and the Technology hereunder.
Without limiting the foregoing, the licenses granted hereunder shall not be
interpreted to limit or derogate AccuMed's right or ability to make, have made,
use, offer to sell, sell, license or to otherwise commercially exploit for its
own benefit the Patents, the Technology, and the Copyrighted Works in any manner
in connection with any products, systems, or processes or licenses outside of
the Field Exclusivity.

        2.5 IMPROVEMENTS. Licensee Improvements will be owned by Licensee.
AccuMed Improvements will be owned by AccuMed. Licensee hereby grants to AccuMed
a non-exclusive license to use Licensee Improvements outside the Field
Exclusivity, solely to the extent Licensee shall have rights therein and
coterminous with the licenses granted to Licensee hereunder. AccuMed
Improvements shall be covered by the license grants under this Agreement solely
to the extent AccuMed shall have rights therein. Each party shall keep the other
party fully apprised of any improvements it may develop for the Licensed Product
and shall give the other party prompt written notice of any of the same, which
shall be given, in any event, not later than ten (10) business days after such
party becomes aware of the same.

        2.6 DUTY TO MARKET. Licensee hereby covenants and agrees that during the
term of this Agreement it will use its best efforts to design, develop,
manufacture, sell, market, and support the Licensed Products as they are deemed
by Licensee to be useful in Licensee's business development within the Field.

        2.7 DUTY TO DELIVER DOCUMENTATION. AccuMed shall at its sole cost and
expense, within forty-five (45) days after execution of this Agreement by
Licensee, deliver to Licensee a tangible and/or electronic copy of all of
AccuMed's documentation of the Patents and the Technology.

                                    SECTION 3
                  LICENSE FEES, ROYALTIES, RECORDS, AND REPORTS

        3.1    GUARANTEED CASH LICENSE FEE. Licensee shall pay AccuMed a
               Guaranteed Cash License Fee equal to [***] (the "Guaranteed Cash
               License Fee"), of which [***] shall be paid by Licensee to
               AccuMed on the date hereof by wire transfer to the account of
               AccuMed designated in writing (and shall be a condition precedent
               to the effectiveness of the license grants hereunder) and the
               remainder of which shall be payable in accordance with the
               following payment schedule:

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       4
<PAGE>   5

                      (i)    [***]
                      (ii)   [***]
                      (iii)  [***]
                      (iv)   [***]
                      (v)    [***]
                      (vi)   [***]

        The payments referred to in (i) through (vi) above shall be made by wire
transfer to the account of AccuMed designated in writing by AccuMed at least two
business days prior to the payment due date. Licensee shall pay AccuMed a [***]%
late fee on the amount of any late payment from the fifth day after the due date
until the payment is made. The Guaranteed Cash License Fee shall be deemed to be
a license issue fee and shall neither be (i) refundable nor (ii) (except as
expressly provided in paragraph (b) of Section 5.1, in Section 5.2, and in
Section 5.3) in any circumstance credited or recoupable against any of the
Required Royalty payments due AccuMed under this Agreement.

        3.2 REQUIRED ROYALTY; CREDIT FOR FIRST $[***]. For the rights and
privileges granted to Licensee under this Agreement, Licensee (subject to
paragraph (b) of Section 5.1, Section 5.2, and Section 5.3) shall pay to AccuMed
from and after the date hereof until the licenses hereunder are terminated in
accordance with this Agreement, a royalty rate equal to the percentage specified
on Schedule 1 of all Sales of any Licensed Product (the "Required Royalty"). A
product is considered subject to a Sale hereunder when payment is collected.
Licensee shall make the Required Royalty payments quarterly on or prior to the
tenth business day following the end of each quarter for which Required
Royalties are owing. The first $[***] of Required Royalties shall be credited
against the Cash/Stock Payment. Licensee's obligation to make quarterly payments
of Required Royalties shall commence with the first quarter in which Required
Royalties in excess of $[***] have been accrued.

        3.3 CASH/STOCK PAYMENT. (a) As part of the consideration paid for the
licenses granted herein, Licensee shall pay AccuMed either $[***] (the
"Cash/Stock Payment") in cash or shares of Licensee's common stock ("Licensee
Common Stock"). On the first anniversary of this Agreement, Licensee shall
notify AccuMed whether it elects to make the Cash/Stock

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       5
<PAGE>   6

Payment in cash or Licensee Common Stock. If Licensee elects to make such
payment in cash, it shall pay the cash to AccuMed within ten business days
following the first anniversary of this Agreement.

               (b) If Licensee elects to make such payment in Licensee Common
Stock, Licensee shall deliver to AccuMed a certificate or certificates
representing the Licensee Common Stock within ten business days following the
date on which the Securities and Exchange Commission (the "SEC") declares
effective the registration statement registering the resale of such shares by
AccuMed, as provided in Section 10. Notwithstanding the foregoing, if the SEC
has not so declared such registration statement effective on or prior to the
ninetieth day following the first anniversary of this Agreement, Licensee shall
make the Cash/Stock Payment to AccuMed in cash within ten business days
following such ninetieth day. The number of shares of Licensee Common Stock
delivered to AccuMed having a fair market value of $[***] shall be determined by
reference to (i) the average closing bid price of the Licensee Common Stock, for
twenty (20) consecutive trading days ending on the date on which the SEC
declares the registration statement effective, as reported by Nasdaq, if the
Licensee Common Stock is traded on the Nasdaq Bulletin Board or SmallCap Market,
or (ii) the average last reported sales price of the Licensee Common Stock, for
twenty (20) consecutive trading days ending on the date on which the SEC
declares the registration statement effective, as reported by the primary
exchange on which the Licensee Common Stock is traded, if the Licensee Common
Stock is traded on a national securities exchange, or by Nasdaq, if the Licensee
Common Stock is traded on the Nasdaq National Market. The Licensee Common Stock,
if issued in payment of the Cash/Stock Payment, shall be fully paid and
non-assessable, and shall be issued without violation of any preemptive rights.

        3.4 STOCK PAYMENT. As part of the consideration paid for the licenses
granted herein, Licensee shall issue to AccuMed a number of shares of Licensee
Common Stock (the "Stock Payment") determined as follows. The number of shares
shall equal to [***]% of the total number of shares of Licensee Common Stock and
any other class of common stock of the Licensee outstanding on the first
anniversary of this Agreement determined as follows. For purposes of this
calculation shares outstanding:

                (i) except as provided in paragraph (ii) below, shall include
               all shares issuable upon exercise of warrants, conversion of
               convertible preferred stock, convertible notes and any other
               securities (other than employee and director stock options)
               outstanding on the first anniversary of this Agreement
               exercisable for or convertible into any class of common stock of
               Licensee;

               (ii) shall include all shares issued and outstanding on the date
               hereof and all shares issued and outstanding or issuable upon
               exercise or conversion of securities sold during the first year
               of this Agreement having aggregate gross proceeds of up to
               $[***]; and shall exclude any shares issued or issuable as a
               result

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       6
<PAGE>   7

               of sales of securities during the first year of this Agreement
               exceeding the $[***] referenced in the immediately preceding
               clause.

Licensee shall deliver to AccuMed a certificate or certificates representing the
Stock Payment within ten business days following the first anniversary of this
Agreement. If AccuMed's board of directors declares a dividend of all or part of
the Stock Payment to AccuMed's stockholders, Licensee shall reimburse AccuMed
for all reasonable, documented expenses related to such dividend distribution.
The Licensee Common Stock issued in payment of the Stock Payment shall be fully
paid and non-assessable, and shall be issued without violation of any preemptive
rights.

        3.5 SCOPE OF ROYALTY. Sales subject to royalty shall not in any way be
limited by territorial limitations or by the source of those revenues, and will
include any revenues which Licensee directs to be paid to any other Person. The
calculation of Sales will be carried out in accordance with generally accepted
accounting principles applied on a consistent basis. Licensee will take all
reasonable and prudent steps necessary to collect monies payable on account of
Licensed Products.

        3.6 AFFILIATED PERSON SALES. If Licensee sells, rents, or offers for use
a Licensed Product or otherwise makes a Sale to any Affiliate, then the Sales
with respect thereto shall be the price or terms at which Licensee should have
made the same Licensed Product available to a bona fide third party on an arms
length basis. No deductions or allowances whatsoever shall be made for the cost
of collections, or for commissions to Licensee's employees, officers, or
directors or any Affiliate.

        3.7 PERIODIC REPORTS. Licensee, on the fifth business day following the
close of each calendar quarter, beginning with the calendar quarter in which
Licensee commences any actual Sales of Licensed Products, shall deliver to
AccuMed a true and accurate written report certified by Licensee's chief
financial officer of all of its Sales activities relating to the Licensed
Product for the immediately preceding calendar quarter to facilitate the proper
computation of the Required Royalty. These reports shall include the following:
(i) true and correct copies of all current product catalogues and price lists of
Licensee; (ii) identification of the quantity and type of any Licensed Products
sold, leased or rented upon which royalties are due; (iii) gross receipts for
such sale, lease or rental; and (iv)royalty due AccuMed.

In addition to the periodic reports described above, Licensee shall provide
AccuMed with copies of Licensee's annual audited financial statements within one
hundred twenty (120) days after the end of Licensee's fiscal year.

        3.8 FINANCIAL RECORDS. Licensee shall keep full, true, and accurate
books of account containing all particulars which may be necessary for the
purpose of showing the royalty amounts payable to AccuMed hereunder. These books
of account shall be kept by Licensee at the usual place where its other books
are kept. These books and their supporting data will be open at reasonable
times, for a period of three (3) years following the end of the calendar year to
which they pertain, for inspection by an independent certified public accountant
retained by

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       7
<PAGE>   8

AccuMed for the purpose of verifying Licensee's royalty statements or Licensee's
compliance with other provisions of this Agreement pursuant to Section 3.9.
Licensee shall prepare or cause the preparation of annual audited financial
statements for the purposes of reporting under Section 3.7.

        3.9 AUDIT RIGHTS. AccuMed shall have the right to have periodic audits
of Licensee performed on not less than fifteen (15) days' advance written notice
by AccuMed to Licensee for the purposes of verifying royalty payments under this
Agreement. AccuMed shall be permitted to perform such audits not more often than
once in any calendar year. AccuMed may, in its discretion, retain the services
of an independent certified public accountant to perform any such audit. AccuMed
shall pay for the services of any such independent certified public accountant,
except as provided in this Section below. AccuMed will notify Licensee if
AccuMed's independent certified public accountant determines that Licensee has
understated the royalties due AccuMed by five percent (5%) or more over a
calendar quarter (a "Royalty Understatement"). If Licensee notifies AccuMed
within fifteen (15) days of such notice that Licensee's own independent
certified public accountant disputes the determination of AccuMed's certified
public accountant as to any Royalty Understatement (a "Licensee Dispute
Notice"), then the parties shall mutually designate a third independent
certified public accountant to audit the royalty payments hereunder. The
determination of such third accountant shall be binding on the parties. If
Licensee does not make a Licensee Dispute Notice or if any such third accountant
also determines that there has been a Royalty Understatement, then Licensee
shall pay to AccuMed, within fifteen (15) days after notice of a Royalty
Understatement by AccuMed or such third accountant, as applicable, (i) the
balance of such Royalty Understatement as determined by AccuMed's accountant,
but if there is a third accountant, as determined by such third accountant, (ii)
a penalty fee equal to five percent (5%) of any such Royalty Understatement plus
interest thereon at a rate equal to one percent (1%) per month or such lesser
amount as required by law, computed from the day on which such royalties were
due and owing to AccuMed, and (iii) the reasonable fees of AccuMed's accountant
for its services and, if applicable, any third accountant for its services. If
any such third accountant determines that there has not been a Royalty
Understatement, then AccuMed shall pay the reasonable fees for the services of
such third accountant.

        3.10 INTEREST. Licensee shall pay AccuMed interest on all royalty
amounts which are past due under this Agreement at an interest rate equal to one
percent (1%) per month (or such lesser amount as required by law). Interest
under this Section shall be computed from the day the royalty amounts are due
and payable under this Agreement.

        3.11 CURRENCY. All payments from Licensee to AccuMed shall be in U.S.
dollars (U.S.$), unless Licensee has been paid by any purchaser of the Licensed
Products in some other currency and AccuMed elects to be paid by Licensee with
regard to that transaction in the same currency.

        3.12 TAXES. The payment to AccuMed of the royalties, fees, compensation,
and other payments provided for in this Agreement shall be free of any taxes,
charges, or remittance fees, whether levied by the federal, state, or municipal
governments in the Territory, or by other authorities, except for such income
tax which may be expressly required by the laws of the

                                       8
<PAGE>   9

governments in the Territory to be paid for the account of AccuMed. The payment
of any such income taxes levied upon or withheld from royalties, fees,
compensations, or other payments due to AccuMed, and the filing of any
information or tax returns with respect thereto, shall be the responsibility of
Licensee, who shall be liable to AccuMed with respect to any amounts, fines, or
penalties arising out of or resulting from any failure, delay, or error in
discharging the aforesaid obligation.

                                    SECTION 4
                              VALIDITY AND MARKING

        4.1 VALIDITY. If Licensee or another challenges the validity of any of
the Patents once issued, Licensee agrees and is obligated to continue paying all
royalties due before such time as a final determination of invalidity and during
the pendency of any such validity challenge, and Licensee is not entitled to any
refund or credit for any such past royalty or Guaranteed Cash License Fee. If
Licensee challenges the validity of any of the Patents, Licensee agrees to pay
AccuMed's reasonable attorneys' fees and all associated costs in defending such
action, unless all of the Claims of each challenged Patent are held invalid or
unenforceable. Licensee agrees and is obligated to continue paying royalty
payments during the pendency of any challenge to the validity of any of the
Patents. If final judgments that are beyond further right of appeal are entered
which finally invalidate all issued Patents, thereafter Licensee's sole remedy
shall be the reduction in the rate of the Required Royalty in accordance with
Section 9.2; and Licensee shall continue thereafter to be obligated to pay such
reduced Required Royalty and any unpaid Guaranteed Cash License Fee, Cash/Stock
Payment and Stock Payment. Licensee shall not challenge the validity of any of
the Technology or the Copyrighted Works.

        4.2 MARKING. As to any Patents issued, Licensee shall mark all Licensed
Products covered by the Claims of such Patent with the following statement, with
the bracketed language completed as appropriate, or, if any Foreign Patent
issues, such other similar statement as may be required under the laws
applicable to the marking of any such Foreign Patent:

               "Licensed by [current corporate name of Licensee] under one or
               more of the following patents: United States Patent Nos. [insert
               the applicable patent numbers for the Patents which have
               issued]."

                                    SECTION 5
                    PROSECUTION; PROTECTION; AND INFRINGEMENT

        5.1 PROSECUTION AND PROTECTION.

               (a) AccuMed shall diligently and in a commercially reasonable
manner prosecute the application for and the issuance of the U.S. Patents and
Foreign Patents that AccuMed, in its sole discretion, decides to prosecute, at
the sole cost and expense of AccuMed. AccuMed shall diligently and in a
commercially reasonable manner maintain issued Patents at AccuMed's sole cost
and expense. If AccuMed determines in its sole discretion for commercial reasons
to abandon prosecution or maintenance of a patent application or issued patent,
as the case may be, in any jurisdiction, Licensee may elect to prosecute such
application or maintain such issued

                                       9
<PAGE>   10

patent in such jurisdiction at its sole expense. In such case, AccuMed shall
assign all rights to Licensee necessary for Licensee to pursue such action.

               (b) Licensee shall notify AccuMed in writing of Licensee's sale
of Licensed Products in any foreign country upon or prior to the date on which
Licensee first sells Licensed Products in such country. If a Foreign Patent
shall not already be pending or issued in such country, AccuMed shall have
twenty-one (21) days from such written notice to notify Licensee in writing
whether or not AccuMed will commence the prosecution of a Foreign Patent in such
country. If AccuMed elects, in such notice, to prosecute a Foreign Patent in
such country, AccuMed will promptly commence the prosecution thereof. If AccuMed
elects, in such notice, not to prosecute a Foreign Patent in such country or if
AccuMed fails to make a timely election, then Licensee may elect to prosecute
such Foreign Patent, at Licensee's sole cost and expense, for and on behalf of
and in the name of AccuMed. Licensee may deduct all reasonable out-of-pocket
costs and expenses, including without limitation, attorneys' fees and filing
costs, incurred by Licensee for its prosecution (in accordance its election
under with this paragraph) of Foreign Patents in any foreign country from the
Required Royalties (but not the Guaranteed Cash License Fee) applicable to that
country under Section 3.2. AccuMed will provide to Licensee all information,
papers, instruments or affidavits required to apply for and obtain Foreign
Patents in AccuMed's name and will provide reasonable assistance to Licensee in
Licensee's efforts to prosecute any Foreign Patents in accordance with its
election under this paragraph. Any such Foreign Patents prosecuted by Licensee
for and on behalf of AccuMed shall be the sole and exclusive property of
AccuMed, but Licensee shall be granted a license thereunder coincident with the
grant under Section 2.1 for all Foreign Patents.

               (c) Except as provided in this Section, for and on behalf of
AccuMed, Licensee shall not prosecute any letters patent in any foreign country
covering any of the Claims of the U. S. Patents or any Foreign Patents. As
requested by AccuMed from time to time, Licensee shall provide reasonable
assistance to AccuMed (at AccuMed's sole cost and expense for the U. S. Patents
and the Foreign Patents in Canada and the European Community but otherwise at
the equal cost and expense of AccuMed and Licensee or Licensee's sole expense as
determined in accordance with paragraph (b) of this Section) in AccuMed's
prosecution of the Patents in accordance with this Section. AccuMed shall
maintain any issued Patents in a commercially reasonable manner. AccuMed shall
use commercially reasonable efforts to maintain the secrecy of its trade secrets
comprising any of the Technology. To the extent Licensee becomes aware of any
matters or events which may affect the validity of the Patents or protection of
the Technology, Licensee shall inform AccuMed of such matters or events within
ten (10) business days after Licensee becomes aware of any such matters or
events.

               (d) Nothing in this Section shall (i) require either AccuMed or
Licensee to prosecute patents in any foreign country or (ii) restrict Licensee
from exercising its exclusive license rights under this Agreement in any foreign
country or throughout the Territory, regardless of whether Licensee or AccuMed
elects to prosecute any application for Foreign Patents therein.

        5.2 INFRINGEMENT BY THIRD PARTIES. Each party shall inform the other
party of any infringement or suspected infringement of the Patents or
infringement (including any misappropriation) of the Technology of which such
party becomes aware within ten (10) business days after such party becomes aware
of any such infringement or suspected

                                       10
<PAGE>   11

infringement. For a period of thirty (30) days after receipt by AccuMed of, or
AccuMed's sending of, such notice of infringement, AccuMed will have the
exclusive right to commence an action and otherwise assert rights in the Patents
and the Technology against any such infringers or suspected infringers and
retain all proceeds of such action or proceeding brought by it and will have the
right at its sole discretion to make any settlement or compromise with the
third-party infringer. If AccuMed shall elect to prosecute any such infringer,
Licensee shall take such steps as are reasonably requested by AccuMed to enable
it to protect its rights under the Patents and under the Technology against any
such infringement or suspected infringement. If (i) AccuMed fails to commence an
action or otherwise assert its rights in the Patents and the Technology against
any such infringers or suspected infringers within such thirty (30) day period
and (ii) Licensee provides AccuMed with the opinion of patent counsel mutually
acceptable to the parties stating that there is a likelihood of infringement or
misappropriation by such suspected infringers (an "Infringement Opinion"), then
Licensee may bring an action or proceeding (including any alternative dispute
resolution process) to enjoin the infringement, to recover damages for it, or
both and AccuMed grants Licensee the right to use AccuMed's name in connection
therewith and will have the right at Licensee's sole discretion to make any
settlement or compromise with the third-party infringer, in accordance with and
subject to the provisions set forth below. If an Infringement Opinion is
delivered to AccuMed and, accordingly, Licensee is permitted to bring such
action, then Licensee may elect to deduct a percentage of its out-of-pocket
costs and expenses (but otherwise will bear all other costs and expenses), which
includes without limitation court costs and attorneys' fees for such action up
to a maximum deduction of fifty percent (the "Fee Percentage") and shall notify
AccuMed of such election and the applicable Fee Percentage when the Infringement
Opinion is delivered by Licensee to AccuMed. Licensee shall be permitted to
deduct from future Guaranteed Cash License Fees, and Required Royalties, as they
become due under this Agreement, that portion of its out-of-pocket expenses in
an amount equal to the Fee Percentage thereof. All proceeds of such action or
proceeding brought by Licensee (if any) shall be shared between AccuMed and
Licensee pro rata in accordance with the Fee Percentage (i.e. AccuMed shall
receive the Fee Percentage of such proceeds and Licensee shall receive the
remainder). If Licensee shall be permitted to bring an action pursuant to this
Section, AccuMed shall take such steps as are reasonably requested by Licensee
to enable it to protect its Licensee rights under the Patents and under the
Technology against any such infringement or suspected infringement.

        5.3 INFRINGEMENT OF THIRD PARTY RIGHTS. If Licensee makes or incurs any
out-of-pocket payments for settlements, damages, and/or royalties owing to third
parties (exclusive of one-half of Licensee's court costs, attorneys' fees and
other expenses of defense) as result of any claim by a third party that the
Patents or Technology incorporated in any Licensed Products infringe or violate
any third party patent, copyright, trademark, trade secret or other proprietary
right, then Licensee may deduct an amount equal to such out-of-pocket payments
from future Guaranteed Cash License Fees or Required Royalties as they become
due under this Agreement. The foregoing remedy will be the exclusive remedy of
Licensee for any third-party claim of infringement or misappropriation.

                                    SECTION 6
                         CONFIDENTIALITY; COLLABORATION

                                       11
<PAGE>   12

        6.1 CONFIDENTIALITY.

               (a) Proprietary Information. Each party will exercise all
reasonable precaution to retain in confidence and not disclose proprietary
information relating to (I) the Patents (except to the extent that the Patents
are or become issued patents) and the Technology, (ii) product designs,
prototypes, schematics, trade secrets (including ideas, formulas, compositions,
inventions (whether patentable or unpatentable and whether or not reduced to
practice), know-how, manufacturing and production processes and techniques,
research and development information, drawings, specifications, designs, bills
of material, and technical data), and embodiments thereof (in whatever form or
medium), (iii) information concerning unsuccessful tests and ideas and
technologies which have not worked, as well as information concerning successful
technologies, (iv) information concerning either party's and its Affiliates' and
subsidiaries' business plans, (v) information which either party compiles and
maintains in databases for its Affiliates' and subsidiaries' internal business
purposes, (vi) information disclosed to either party in documents marked
"confidential," (vii) any software, firmware, documents (including, without
limitation, manuals, manuscripts, drawings, blueprints, schematics, engineering
logbooks, and laboratory notebooks), and methodologies, and (viii) other things
and ideas which one party may disclose to the other party in connection with
this Agreement or which one party may commission the other party to create,
improve or develop, and any other information which a party is informed that the
other party regards as confidential ("Proprietary Information"); provided
however that, notwithstanding anything contained herein to the contrary, (a)
such Proprietary Information shall only include such information (1) that each
party actually treats as confidential and (2) with respect to which each party
takes appropriate steps to safeguard from disclosure to others and (b) such
Proprietary Information described in clauses (ii) through (viii) above shall
only include such information which one party may disclose to and which is
received by the other party.

               (b) Non-disclosure. Each party shall receive, develop and hold
Proprietary Information in confidence and shall use its best efforts to preserve
the confidentiality of such Proprietary Information consistent with the manner
in which it protects its own most confidential business information. Disclosures
of Proprietary Information to a party's personnel shall be limited to
"designated employees" with a need to know same and made solely as necessary to
enable them to exercise their employment or fiduciary duties. Each party shall
require each of its designated employees to sign a confidentiality agreement
prior to the time such individual is first allowed access to Proprietary
Information.

               (c) Remedies. Each party acknowledges that its breach of the
foregoing confidentiality obligations would cause the other party irreparable
injury for which there would be no adequate remedy at law. Accordingly, each
party agrees that if such breach or threatened breach is proved by the other
party, the other party shall be entitled to appropriate injunctive relief and
such other relief as the court deems equitable in the circumstances.

               (d) Duration. The parties' confidentiality obligations under this
Section shall remain in effect until the later of (I) five years after the
termination of this Agreement and (ii) so long as such information remains
protectable as a trade secret under applicable law, even if dealings between
Licensee and AccuMed have ceased.

                                       12
<PAGE>   13

               (e) Public Domain. This Section shall not restrict the rights of
a party to disclose information that:

                      (i) is requested or consented to be disclosed by the owner
thereof in writing;

                      (ii) is or becomes generally available to the public other
than by breach of this Agreement or other obligation of confidentiality; or

                      (iii) one party is required by law to disclose provided,
however, prior to any such disclosure, such party shall immediately notify the
other party in writing if such party believes that there will be a legal
requirement to disclose, to enable the other party to determine a more
appropriate means of disclosure and so that the other party is provided the
opportunity to contest such disclosure requirement through legal means.

        6.2 COLLABORATION WITH ACCUMED PERSONNEL. From the date hereof through
May 30, 2000, AccuMed will make available to Licensee the limited time and
effort of Norman J. Pressman and AccuMed's technical/scientific research and
development personnel to assist and support Licensee in its capital raising
activities, provided that Licensee promptly reimburse AccuMed for the
reasonable, documented out-of-pocket expenses of such personnel in performing
such assistance and support.

                                    SECTION 7
                     GENERAL REPRESENTATIONS AND WARRANTIES

        7.1 REPRESENTATIONS OF LICENSEE. Licensee hereby represents and warrants
to AccuMed, as of the date hereof, as follows:

               (a) Licensee: (i) is a corporation duly formed and validly
existing under the laws of the State of New York; (ii) has the power and
authority to own its property and to carry on its business as now conducted or
as presently contemplated; and (iii) has the power and authority to execute,
deliver and perform this Agreement.

               (b) The execution, delivery and performance by Licensee of this
Agreement: (i) have been duly authorized by all requisite action on the part of
Licensee, including any requisite approval of its board of directors; (ii) do
not violate any provision of law, the certificate of incorporation or bylaws of
Licensee, or any applicable order of any court or other governmental agency;
(iii) do not breach of the terms of any agreement, document, or instrument to
which Licensee is a party or which is binding upon Licensee or its property; and
(iv) do not require the approval, consent, authorization or act of, or the
making of any declaration, filing or registration with, any person or entity
(other than as required by Licensee pursuant to Section 11.2).

                                       13
<PAGE>   14

               (c) This Agreement constitutes a legal, valid and binding
obligation of Licensee, enforceable against Licensee in accordance with its
terms, subject, as to enforcement, to applicable bankruptcy, reorganization,
insolvency and similar laws affecting creditors' rights generally and to
moratorium laws from time to time in effect and to the extent that such
enforcement is subject to the principles of equity in a proceeding at law or in
equity.

        7.2 REPRESENTATIONS OF ACCUMED. AccuMed hereby represents and warrants
to Licensee, as of the date hereof, as follows:

               (a) AccuMed: (i) is a corporation duly organized and validly
existing under the laws of the State of Delaware; (ii) has the power and
authority to own its property and to carry on its business as now conducted or
as presently contemplated; and (iii) has the power and authority to execute,
deliver and perform this Agreement.

               (b) The execution, delivery and performance by AccuMed of this
Agreement: (i) have been duly authorized by all requisite corporate action on
the part of AccuMed, including any requisite approval of its board of directors;
(ii) do not violate any provision of law, the certificate of incorporation or
bylaws of AccuMed, or any applicable order of any court or other governmental
agency; (iii) do not breach of the terms of any agreement, document, or
instrument to which Licensee is a party or which is binding upon AccuMed or its
property; and (iv) do not, subject to Licensee's obligations under Section 11.2,
require the approval, consent, authorization or act of, or the making of any
declaration, filing or registration with, any person or entity by AccuMed.

               (c) This Agreement constitutes a legal, valid and binding
obligation of AccuMed, enforceable against AccuMed in accordance with its terms,
subject, as to enforcement, to applicable bankruptcy, reorganization, insolvency
and similar laws affecting creditors' rights generally and to moratorium laws
from time to time in effect and to the extent that such enforcement is subject
to the principles of equity in a proceeding at law or in equity.

               (d) The Patents and Technology licensed hereunder constitute all
of the Patents and Technology related to the Field owned by AccuMed.

               (e) AccuMed has not received any notice of, and to AccuMed's
knowledge there is no basis to support, any third party claim that the Patents
or Technology infringe upon or otherwise violate the rights of a third party.

               (f) AccuMed does not have pending, and to AccuMed's knowledge,
there is no basis to assert, any claim against any current or former employee
for misappropriation of the Patents or Technology.

               (g) AccuMed has good and clear title to the Technology and
Patents, and there are no liens or encumbrances thereon.

                                    SECTION 8
                              DEFAULT AND REMEDIES

                                       14
<PAGE>   15

        8.1 TERMINATION DEFAULT. The occurrence of the following events shall
constitute a "Termination Default" under this Agreement, Licensee fails to pay
to AccuMed any of the Guaranteed Cash License Fee, the Required Royalty, or any
other royalty payments, interest, fees, or other amounts due and owing to
AccuMed and any such failure to pay shall continue for more than fifteen
(15)days after written notice thereof from AccuMed to Licensee.

         8.2 REMEDIES. If any Termination Default occurs, AccuMed may elect, at
its option, any or all of the following: (a) to terminate or suspend any or all
of the licenses granted under this Agreement; or (b) convert any or all of the
licenses granted under this Agreement to non-exclusive licenses. This Agreement
and the licenses granted by AccuMed to Licensee hereunder cannot be terminated
for any default of any term or condition of this Agreement other than a
Termination Default. If a default hereunder other than a Termination Default
occurs, the non-defaulting or non-breaching party may not terminate this
Agreement but may seek monetary damages or appropriate injunctive relief (other
than termination of the licenses hereunder) from the defaulting or breaching
party in a court or arbitration body of competent jurisdiction.

          8.3 CUMULATION. Each party shall have, in addition to any other rights
and remedies contained in this Agreement, all of the rights and remedies
available under applicable laws, all of which rights and remedies shall be
cumulative, and non-exclusive, to the extent permitted by law.

          8.4 EFFECTS OF WAIVER. The failure of either party to exercise any of
its rights hereunder shall not constitute a waiver of any of such rights, or
other rights or remedies available to that party hereunder or under applicable
law.

          8.5 NO WAIVER. No delay or omission of either party to exercise any
right under this Agreement shall impair such right or be construed to be a
waiver of any Default or an acquiescence therein, and any single or partial
exercise of any such right shall not preclude other or further exercise thereof
or the exercise of any other right, and no waiver, amendment or other variation
of the terms, conditions or provisions of this Agreement whatsoever shall be
valid unless in a writing signed by that party and then only to the extent in
such writing specifically set forth. All remedies contained in this Agreement,
or by law afforded shall be cumulative.

                                    SECTION 9
       TERM AND TERMINATION; ACCUMED BUY-BACK; PARTIAL REFUND OF PAYMENTS

        9.1 TERM. Unless earlier terminated by AccuMed pursuant to Section 8.2
or by Licensee or AccuMed pursuant to Section 9.3, this Agreement and the
licenses granted herein shall terminate upon the later of (x) 20 years from the
effective date hereof and (y) if any Patent shall issue, the expiration or
termination of the last issued Patent, including any modifications, extensions,
or reissues thereof.

        9.2 EFFECT OF PATENT INVALIDATION. As to any Patents that have or shall
issue and, thereafter, if all Claims of all of the Patents should be finally
determined to be invalid by a decision of a court of competent jurisdiction that
is final beyond further right of appeal, then the

                                       15
<PAGE>   16

rate of the Required Royalty shall be reduced by one-half of one percent (0.5%).
Licensee acknowledges that the licenses hereunder in the Technology independent
of any issued and valid Patent are valuable and reasonable consideration for the
Required Royalty. Licensee shall pay (subject to paragraph (b) of Section 5.1,
Section 5.2, and Section 5.3) all Required Royalties (at the percentage rate
specified on Schedule 1) due and payable before any such final determination of
invalidity and during the pendency of any validity challenge, and Licensee is
not entitled to any refund or credit for any past Required Royalties, or the
Guaranteed Cash License Fee payments, the Cash/Stock Payment or the Stock
Payment. Licensee shall pay all royalty payments accruing during the pendency of
any challenge to the validity of any of the Patents.

        9.3 TERMINATION BY LICENSEE; ACCUMED BUY-BACK OF LICENSED RIGHTS.

               (a) Non-cancellation Period. Licensee shall not be entitled to
terminate its obligations under this Agreement until the earlier to occur of (i)
the fifth anniversary date of this Agreement and (ii) AccuMed's receipt of the
Guaranteed Cash License Fee, the Cash/Stock Payment and the Stock Payment. (The
period from and after the date of execution of this Agreement and ending upon
the earlier event described in the immediately preceding sentence is the
"Non-Cancellation Period"). After the commencement of the Non-Cancellation
Period, Licensee may, at its election, (x) if Licensee shall have notified
AccuMed after the Non-Cancellation Period that in Licensee's reasonable
determination the commercial exploitation of the Licensed Product is not
commercially viable, terminate the exclusivity of the licenses granted hereunder
upon thirty (30) days' written notice to AccuMed or (y) terminate this
Agreement. If Licensee shall elect to terminate the exclusivity in accordance
with clause (x) above, then Licensee shall continue to be obligated to make
payments to AccuMed of any Required Royalties. Licensee shall pay all amounts
due and payable to AccuMed hereunder before any such election to terminate the
exclusivity in accordance with clause (x) above and Licensee is not entitled to
any refund or credit for any past Required Royalties, or the Guaranteed Cash
License Fee payments, Cash/Stock Payment or Stock Payment.

               (b) AccuMed Buy-back of Licensed Rights. If by the [***]
anniversary of this Agreement AccuMed has not received an aggregate of $[***] in
Required Royalty payments, excluding the first $[***] in Required Royalty
payments, AccuMed may elect to terminate this Agreement on 30 days' written
notice to Licensee; provided however, that AccuMed shall repurchase all rights
granted to Licensee hereunder (except as otherwise provided in this Section
9.3(b)); provided further, that Licensee may unilaterally prevent such
termination and repurchase if Licensee pays AccuMed within such 30-day period
$[***] in cash by wire transfer to the account designated by AccuMed. The
repurchase payment shall equal the aggregate amount of

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       16
<PAGE>   17

(i)[***], and (ii)[***]. The only rights of Licensee to survive such repurchase
shall be the licenses granted in Sections 2.1, 2.2 and 2.3 on a royalty free,
non-exclusive basis for use only in connection with automation of Licensee's
Trend CytoGram(registered trademark) in the Field.

        9.4 EFFECT OF TERMINATION. Upon any termination of this Agreement
becoming effective, Licensee shall be relieved of all duties and obligations,
except that Licensee shall in any event be obligated to pay to AccuMed (i)
royalties and interest accrued and unpaid up to that time and royalties and
interest subsequently due on Licensed Products used, sold, leased or rented for
use in connection with the rights granted under this license prior to
termination becoming effective and (ii) any unpaid Required Royalties accrued
and unpaid as of the time of such termination. Licensee shall under no
circumstances be entitled to a return of monies theretofore paid or to an
abatement of royalties and interest accrued and unpaid on the effective date of
termination, including royalties and interest on Licensed Products used, rented
or sold in connection with the rights granted under this license prior to the
effective date of termination. If this Agreement shall terminate, then Licensee
shall, upon request of AccuMed, promptly return to AccuMed (or, at AccuMed's
discretion, destroy and certify to AccuMed the destruction of) the originals and
all copies of any and all materials in its possession or under its control to
the extent they are Copyrighted Works. Upon any election by Licensee in
accordance with this Agreement to convert the licenses hereunder to
non-exclusive licenses, then Licensee shall, upon request of AccuMed, promptly
return to AccuMed copies of any and all materials and documents in its
possession or under its control to the extent these materials relate in any
manner to the Licensed Product.

        9.5 SURVIVAL OF CERTAIN TERMS. Notwithstanding the termination of this
Agreement as provided above, Sections 2.5, 5.3, 6.1, 8.1, 8.2, 8.3, 8.4, 8.5,
9.1, 9.2, 9.3, 9.4, 9.5, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8 11.9,
and 11.10 shall survive the termination of this Agreement. All representations,
warranties, indemnities and covenants contained in this Agreement shall continue
in full force and effect and shall survive notwithstanding the final payments of
all amounts due hereunder or the termination of this Agreement in any manner
whatsoever.

        9.6 TECHNOLOGY ESCROW. Within 45 days following the date hereof, AccuMed
shall deposit into escrow documentation, in the forms mutually agreed by the
parties, of all the Technology and Patents, including without limitation
technical drawings, (the "Escrow"). AccuMed shall provide Licensee a listing of
all documentation placed in the Escrow. The Escrow shall provide that upon
AccuMed filing for bankruptcy protection, or ceasing to do business and AccuMed
has not assigned its obligations hereunder pursuant to Section 11.8, then the
contents of the Escrow shall be released to Licensee.

                                   SECTION 10
            REGISTRATION OF LICENSEE COMMON STOCK; RESALE LIMITATIONS

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       17
<PAGE>   18

        10.1 LISTING OF LICENSEE COMMON STOCK. Licensee shall take such actions
as are necessary to have the Licensee Common Stock which is issued to AccuMed to
be included for trading on the Nasdaq Bulletin Board or in such Nasdaq market or
stock exchange on which the Licensee Common Stock is traded at the time the
Licensee Common Stock is issued to AccuMed.

        10.2 REGISTRATION UNDER SECURITIES ACT. (a) Licensee shall register for
resale all shares of Licensee Common Stock issued to AccuMed pursuant to this
Agreement (the "Registrable Securities") under the Securities Act of 1933, as
amended (the "Act"). Licensee shall prepare and file with the SEC a registration
statement under the Act covering the Registrable Securities and shall use its
reasonable best efforts to cause such registration statement to become
effective.

               (b) In the event that at the time Licensee is required to
register the Registrable Securities Licensee is in the process of preparing a
registration statement under the Act relating to an underwritten public
offering, then no holder of securities of Licensee, including Requesting
Holders, may include securities in such registration if in the good faith
judgment of the managing underwriter of such public offering the inclusion of
such securities would interfere with the successful marketing of the securities
being underwritten. Shares to be excluded from an underwritten public offering
shall be selected in a manner provided in this Section 10.3. To the extent only
a portion of the Registrable Securities held by AccuMed is included in the
underwritten public offering, a registration statement covering those
Registrable Securities which are excluded from the underwritten public offering
will be filed within 180 days of the consummation of the underwritten public
offering.

               (c) Licensee shall pay the expenses described in Section 10.5 for
the registration statement filed pursuant hereto, except for underwriting
discounts and commissions and legal fees of AccuMed, which shall be borne by
AccuMed.

        10.3 UNDERWRITTEN OFFERING. If any registration pursuant hereto shall be
underwritten in whole or in part, Licensee may require that the Registrable
Securities be included in the underwriting on the same terms and conditions as
the securities otherwise being sold through the underwriters. In the event that
the Registrable Securities together with any other shares which have similar
registration rights (such shares and the Registrable Securities being
collectively referred to as the "Requested Stock") would, in the good faith
judgment of the managing underwriter of such public offering, reduce the number
of shares to be offered by Licensee or interfere with the successful marketing
of the shares of stock offered by Licensee, the number of shares of Requested
Stock otherwise to be included in the underwritten public offering may be
reduced pro rata (by number of shares) among the holders thereof requesting such
registration or excluded in their entirety if so required by the underwriter. To
the extent only a portion of the Requested Stock is included in the underwritten
public offering, those shares of Requested Stock which are thus excluded from
the underwritten public offering shall be withheld from the market by the
holders thereof for a period, not to exceed 180 days, which the managing
underwriter reasonably determines is necessary in order to effect the
underwritten public offering. A registration statement covering those shares of
Requested Stock excluded from the underwritten offering will be filed within 180
days of the consummation of the underwritten public offering.

                                       18
<PAGE>   19

        10.4 REGISTRATION PROCEDURES. Licensee will:

               (a) prepare and file with the SEC a registration statement with
respect to the Registrable Securities, and use its reasonable best efforts to
cause such registration statement to become and remain effective until the
Registrable Securities are freely salable without the volume limitations of Rule
144;

               (b) prepare and file with the SEC such amendments to such
registration statement and supplements to the prospectus contained therein as
may be necessary to keep such registration statement effective until the
Registrable Securities are freely salable without the volume limitations of Rule
144;

               (c) furnish to AccuMed and to the underwriters of the securities
being registered such reasonable number of copies of the registration statement,
preliminary prospectus, final prospectus and such other documents as such
underwriters may reasonably request in order to facilitate the public offering
of such securities;

               (d) use its reasonable best efforts to register or qualify the
securities covered by such registration statement under such state securities or
blue sky laws of such jurisdictions as AccuMed may reasonably request in writing
within twenty (20) days following the original filing of such registration
statement, except that Licensee shall not for any purpose be required to execute
a general consent to service of process or to qualify to do business as a
foreign corporation in any jurisdiction wherein it is not so qualified;

               (e) notify AccuMed, promptly after it shall receive notice
thereof, of the time when such registration statement has become effective or a
supplement to any prospectus forming a part of such registration statement has
been filed;

               (f) notify AccuMed promptly of any request by the SEC for the
amending or supplementing of such registration statement or prospectus or for
additional information;

               (g) prepare and file with the SEC, promptly upon the request of
AccuMed, any amendments or supplements to such registration statement or
prospectus which, in the opinion of counsel for AccuMed (and concurred in by
counsel for Licensee), is required under the Act or the rules and regulations
thereunder in connection with the distribution of Registrable Securities by
AccuMed;

               (h) prepare and promptly file with the SEC and promptly notify
AccuMed of the filing of such amendment or supplement to such registration
statement or prospectus as may be necessary to correct any statements or
omissions if, at the time when a prospectus relating to such securities is
required to be delivered under the Act, any event shall have occurred as the
result of which any such prospectus or any other prospectus as then in effect
would include an untrue statement of a material fact or omit to state any
material fact necessary to make the

                                       19
<PAGE>   20

statements therein, in the light of the circumstances in which they were made,
not misleading; and

               (i) advise AccuMed, promptly after it shall receive notice or
obtain knowledge thereof, of the issuance of any stop order by the SEC
suspending the effectiveness of such registration statement or the initiation or
threatening of any proceeding for that purpose and promptly use its reasonable
best efforts to prevent the issuance of any stop order or to obtain its
withdrawal if such stop order should be issued.

        10.5 EXPENSES.

               (a) All fees, costs and expenses of and incidental to
registration hereunder, inclusion and public offering (as specified in paragraph
(b) below) in connection therewith shall be borne by Licensee, provided,
however, that AccuMed shall bear its pro rata share of the underwriting discount
and commissions and transfer taxes.

               (b) The fees, costs and expenses of registration to be borne by
Licensee as provided in paragraph (a) above shall include, without limitation,
all registration, filing, and NASD fees, printing expenses, fees and
disbursements of counsel and accountants for Licensee, and all legal fees and
disbursements and other expenses of complying with state securities or blue sky
laws of any jurisdictions in which the securities to be offered are to be
registered and qualified. Fees and disbursements of counsel and accountants for
AccuMed and any other expenses incurred by AccuMed not expressly included above
shall be borne by the AccuMed.

        10.6 INDEMNIFICATION.

               (a) Licensee will indemnify and hold harmless AccuMed, its
directors and officers, and any underwriter (as defined in the Act) for AccuMed
and each person, if any, who controls AccuMed or such underwriter within the
meaning of the Act, from and against, and will reimburse AccuMed and each such
underwriter and controlling person with respect to, any and all loss, damage,
liability, cost and expense to which AccuMed or any such underwriter or
controlling person may become subject under the Act or otherwise, insofar as
such losses, damages, liabilities, costs or expenses are caused by any untrue
statement or alleged untrue statement of any material fact contained in such
registration statement, any prospectus contained therein or any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances in which
they were made, not misleading; provided, however, that Licensee will not be
liable in any such case to the extent that any such loss, damage, liability,
cost or expenses arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission so made in conformity with
information furnished by AccuMed, such underwriter or such controlling person in
writing specifically for use in the preparation thereof.

                                       20
<PAGE>   21

               (b) AccuMed will indemnify and hold harmless Licensee, its
directors and officers, any controlling person and any underwriter from and
against, and will reimburse Licensee, its directors and officers, any
controlling person and any underwriter with respect to, any and all loss,
damage, liability, cost or expense to which Licensee or any controlling person
and/or any underwriter may become subject under the Act or otherwise, insofar as
such losses, damages, liabilities, costs or expenses are caused by any untrue
statement or alleged untrue statement of any material fact contained in such
registration statement, any prospectus contained therein or any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances in which
they were made, not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or
alleged omission was so made in reliance upon and in strict conformity with
written information furnished by or on behalf of AccuMed specifically for use in
the preparation thereof.

               (c) Promptly after receipt by an indemnified party pursuant to
the provisions of paragraph (a) or (b) of this Section 10.6 of notice of the
commencement of any action involving the subject matter of the foregoing
indemnity provisions such indemnified party will, if a claim thereof is to be
made against the indemnifying party pursuant to the provisions of said paragraph
(a) or (b), promptly notify the indemnifying party of the commencement thereof;
but the omission to so notify the indemnifying party will not relieve it from
any liability which it may have to any indemnified party otherwise than
hereunder. In case such action is brought against any indemnified party and it
notifies the indemnifying party of the commencement thereof, the indemnifying
party shall have the right to participate in, and, to the extent that it may
wish, jointly with any other indemnifying party similarly notified, to assume
the defense thereof, with counsel satisfactory to such indemnified party,
provided, however, if the defendants in any action include both the indemnified
party and the indemnifying party and the indemnified party shall have reasonably
concluded that there may be legal defenses available to it and/or other
indemnified parties which are different from or in addition to those available
to the indemnified party, or if there is a conflict of interest which would
prevent counsel for the indemnifying party from also representing the
indemnified party, the indemnified party or parties have the right to select
separate counsel to participate in the defense of such action on behalf of such
indemnified party or parties. After notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof, the
indemnifying party will not be liable to such indemnified party pursuant to the
provisions of said paragraph (a) or (b) for any legal or other expense
subsequently incurred by such indemnified party in connection with the defense
thereof other than reasonable costs of investigation, unless (i) the indemnified
party shall have employed counsel in accordance with the provisions of the
preceding sentence, (ii) the indemnifying party shall not have employed counsel
satisfactory to the indemnified party to represent the indemnified party within
a reasonable time after the notice of the commencement of the action or (iii)
the indemnifying party has authorized the employment of counsel for the
indemnified party at the expense of the indemnifying party.

                                       21
<PAGE>   22

        10.7 RESALE LIMITATIONS. During each of the first four 30-day periods
beginning on the date on which Licensee delivers to AccuMed a certificate or
certificates representing the Cash/Stock Payment, AccuMed shall not sell,
transfer or otherwise dispose of more than 25% of the total number of those
shares of Licensee Common Stock constituting the Cash/Stock Payment.

                                   SECTION 11
                            MISCELLANEOUS PROVISIONS

        11.1 USE OF BRANDING AND NAMES. As to any Licensed Product delivered
hereunder which bears branding of an AccuMed trademark, trade name or service
mark, Licensee shall not remove or obscure such branding. Licensee may negotiate
with AccuMed to deliver Licensed Products under private labeling on mutually
acceptable terms.

        11.2 GOVERNMENT AUTHORIZATION. Licensee assumes the obligation at all
times, and at its own expense, of complying with all laws, requirements, and
regulations of the government of the Territory affecting or relating to this
Agreement or the Licensed Product.

        11.3 LIMITATION OF LIABILITY AND WARRANTIES; INDEMNIFICATION.

               (a) AccuMed DISCLAIMS ANY WARRANTIES, INCLUDING WITHOUT
LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, FOR ANY INFORMATION OR THE RESULTS OF USING ANY INTELLECTUAL PROPERTY
LICENSED UNDER THIS AGREEMENT WITH RESPECT TO Licensee OR ANY PURCHASER OF
LICENSED PRODUCTS, OR (EXCEPT AS EXPRESSLY PROVIDED IN SECTION 5.3) INTELLECTUAL
PROPERTY INFRINGEMENT RELATED IN ANY WAY TO THIS AGREEMENT.

               (b) Notwithstanding anything to the contrary contained herein, no
party shall, under any circumstances, be liable to any other party for
consequential, incidental, or special damages of the other party, including but
not limited to, lost profits, even if such party has been apprised of the
likelihood of such damages.

               (c) Licensee shall fully protect, indemnify and hold harmless
AccuMed and its subsidiaries, Affiliates and their officers, directors, and
employees from and against any and all costs, expenses, liabilities, or claims
of whatsoever nature or kind of any injury or damage, including, without
limitation, consequential damages, to third persons or property of third
persons, based upon or arising directly out of or resulting directly from:

                      (i) Any breach by Licensee of any of its obligations or
covenants contained herein;

                                       22
<PAGE>   23

                      (ii) Licensee's or its agent's manufacture, use,
servicing, maintenance, or sales of the Licensed Products, or parts thereof;

                      (iii) Any claims alleging product liability, false or
misleading advertising, disease or death of any person, negligence or other
tortious acts or omissions based on the design and application of the Licensed
Products; or

                      (iv) Any claims for Licensee's negligent or willful acts
or omissions.

               (d) If Licensee or any of its customers, distributors, agents, or
dealers is charged with or sued for infringement of any Patent by reason of
having manufactured, used, offered to sell, or sold any of the Licensed Products
within the scope of this Agreement herein granted, Licensee shall have the sole
responsibility for the investigation of each such charge or suit of
infringement, the defense of each such charge or suit, and the settlement of
each charge or suit.

               (e) From and after the date of any first Sale of any Licensed
Product and during the term of this Agreement, Licensee shall maintain at its
own expense comprehensive general liability insurance for claims for damages
arising from bodily injury (including death) and property damages caused by, or
arising out of, acts or omissions of its employees and shall name AccuMed as an
additional insured thereon. The minimum limits of such insurance will be
$1,000,000 per individual; $2,000,000 per accident involving bodily injury; and
$1,000,000 per accident involving property damage. Maintenance of such insurance
coverage shall not relieve Licensee of any responsibility under this Agreement
for damages in excess of such insurance limits. Licensee shall name AccuMed as
an additional insured on its general commercial liability insurance policies,
and Licensee shall furnish or cause to be furnished to AccuMed a certificate of
such insurance promptly upon request by AccuMed. Any such insurance policy shall
provide that the insurer shall give AccuMed at least thirty days' prior written
notice of any impending cancellation, nonrenewal, expiration, or reduction in
coverage of the insurance.

        11.4 ENTIRE AGREEMENT. This Agreement, together with the Schedules
incorporated by reference herein and the Mutual Non-disclosure Agreement
effective December 1, 1999 between the parties, constitutes the entire agreement
between AccuMed and Licensee relating to the subject matter hereof. There are no
terms, obligations, covenants, representations, statements, or conditions other
than those contained herein and therein. No variation or modification of this
Agreement or waiver of any of the terms or provisions hereof shall be deemed
valid unless made in a writing signed by all parties hereto.

        11.5 NOTICES. All notices and other communications required or desired
to be served, given, or delivered hereunder shall be made in writing or by a
telecommunications device capable of creating a written record and shall be
addressed to the party to be notified as follows:

                                       23
<PAGE>   24

If to AccuMed:

920 N. Franklin St., Ste. 401
Chicago, IL 60610

Attn: Paul F. Lavallee
Chairman and Chief Executive Officer

Telephone no. 312-642-9200
Telecopy no. 312-642-3101

If to Licensee:

BCAM International, Inc.
1800 Walt Whitman Road
Melville, NY 11747

Attn: Michael Strauss
Chairman, President and Chief Executive Officer
Telephone no.  516-752-3550
Telecopy no.    516-752-3558

or, as to each party, at such other address as designated by such party in a
written notice to the other party. Notices shall be deemed to have been duly
given (i) if delivered personally or otherwise actually received, (ii) if sent
by overnight delivery service, (iii) if mailed by first class United States
mail, postage prepaid, registered or certified, with return receipt requested,
or (iv) if sent by telecopy. Notice mailed as provided in clause (iii) above
shall be effective upon the expiration of three (3) business days after its
deposit in the United States mail and notice sent as provided in clause (iv)
above shall be effective upon transmission. Notice given in any other manner
described in this paragraph shall be effective upon receipt by the addressee
thereof; provided, however, that if any notice is tendered to an addressee and
delivery thereof is refused by such addressee, such notice shall be effective
upon such tender.

        11.6 HEADINGS. The headings appearing at the beginning of the numbered
articles and sections hereof have been inserted for convenience only and do not
constitute any part of this Agreement.

        11.7 INVALID SECTIONS. Should any one section, or portion thereof, of
this Agreement be held invalid or invalidated by reason of any law, statute or
regulation existing now or in the future in any jurisdiction by any court of
competent jurisdiction or by a legally enforceable directive of any governmental
body, such section or portion thereof shall be validly reformed so as to
approximate the intent of the parties as nearly as possible, and, if
unenforceable, shall be divisible and deleted in such jurisdiction; and
otherwise this Agreement shall not be affected.

                                       24
<PAGE>   25

        11.8 SUCCESSION AND ASSIGNMENT. This Agreement shall be binding upon and
inure to the benefit of Licensee and its successors and assignees permitted
hereunder and AccuMed and its successors and assignees permitted hereunder.
Licensee shall not assign this Agreement, except in a sale of substantially all
of the assets or equity shares of Licensee, to, or through a merger of Licensee
into, another entity which agrees in writing to be bound by this Agreement.
AccuMed shall not assign this Agreement, except in a sale of substantially all
of the assets or equity shares of AccuMed to, or through a merger of AccuMed
into, another entity which agrees in writing to be bound by this Agreement.

         11.9 GOVERNING LAW; JURISDICTION. This Agreement shall be considered as
having been made in the United States of America and shall be construed and the
respective rights of the parties determined in accordance with the laws of the
State of Illinois. Each party hereto agrees that any legal action or proceeding
arising hereunder shall be brought either in federal or state courts located in
Cook County, Illinois and irrevocably submit themselves to the jurisdiction of
those courts.

         11.10 INDEPENDENT CONTRACTORS. Each party hereto acknowledges that it
is and will be an independent contractor and under no circumstances shall such
be considered an agent, employee, partner or joint venturer of or with any other
party hereto. No authority or right is granted to any party to assume or create
any obligation or responsibility, express or implied, on behalf of or in the
name of any other party.

         11.11 FIRST NOTIFICATION. AccuMed shall notify Licensee within five
business days after receiving a bona fide offer to purchase substantially all of
its assets or to be acquired in a merger, or following the date on which
AccuMed's board of directors adopts a resolution directing management to seek
such an offer.

         11.12 PRESS RELEASES. AccuMed and Licensee shall issue, individually or
jointly, an initial press release or releases disclosing execution of this
Agreement. If the initial press release is joint, the parties will mutually
agree to the language. If the initial press releases as individual, each party
must approve the other party's language, which approval will not be unreasonably
withheld. Neither AccuMed nor Licensee shall issue a press release or make any
other public announcement regarding the subject matter of this Agreement without
the prior agreement of the other party, unless the releasing party, in good
faith, believes it is required to make such announcement under the federal
securities laws or applicable rules of Nasdaq or the stock exchange on which its
stock is quoted or traded.

         11.13 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be considered an original, and all of which
together shall constitute one and the same instrument.

               IN WITNESS WHEREOF, the parties hereto have caused this Patent
and Technology License Agreement to be executed as of the day and year first
above written.

                                       25
<PAGE>   26

ACCUMED INTERNATIONAL, INC.

By:  /s/ Paul F. Lavallee
     ------------------------------
     Paul F. Lavallee
     Chairman and Chief Executive Officer

BCAM INTERNATIONAL, INC.

By:  /s/ Michael Strauss
     ------------------------------
      Michael Strauss
      Chairman, President, and Chief Executive Officer

                                       26<PAGE>   1
                                                                   Exhibit 10.30

                        LICENSE AND DEVELOPMENT AGREEMENT

        This Agreement is entered as of March 24, 2000 (the "Effective Date") by
and between AccuMed International, Inc. ("AccuMed"), a Delaware corporation,
with a place of business at 920 N. Franklin, Suite 402, Chicago, IL 60610 and
Ventana Medical Systems, Inc. ("Ventana"), a Delaware corporation, with a place
of business at 3865 N. Business Center Drive, Tucson, AZ 85705.

1.      DEFINITIONS.

               "AccuMed Imaging Assets" shall mean all the assets, properties,
rights, titles and interests of every kind and nature, whether tangible or
intangible, worldwide related to AccuMed's imaging products, systems, or
services, including but not limited to fixed assets, equipment, tooling,
intellectual property rights, designs, software, and rights existing under
agreements of any type (including but not limited to development and marketing
contracts).

               "AccuMed Intellectual Property Rights" shall mean all
intellectual property rights now or hereafter owned, licensed, or controlled by
AccuMed or any of its Subsidiaries, including but not limited to AccuMed Patent
Rights and AccuMed Technical Information, and any other patent rights,
copyrights, trademarks, and trade secret rights of AccuMed.

               "AccuMed Patent Rights" shall mean any patent rights (including
rights to issued patents and pending patent applications) now or hereafter
owned, licensed, or controlled by AccuMed or any of its Subsidiaries during the
term of this Agreement, including but not limited to rights to the patents and
patent applications listed in Exhibit 1-1 (along with any divisionals,
continuations, continuations-in-part, reissues, re-examinations,
re-registrations or extensions thereof).

               "AccuMed Software" shall mean AccuMed's pre-existing and
later-developed software, tools, modules, products, and related documentation,
and any updates made thereto, in both object code and source code form including
but not limited to related Source Code owned by AccuMed. AccuMed Software
includes, but is not limited to, any AccuMed software or data incorporated into
any Software Products or other deliverables provided to Ventana under this
Agreement.

               "AccuMed Technical Information" shall mean all of AccuMed's trade
secrets, information, and know-how, now or hereafter owned, licensed or
controlled by AccuMed or any of its Subsidiaries during the term of this
Agreement.

               "Alpha Testing" shall mean the alpha testing of Engineering
Prototypes of the imaging hardware platform AccuMed will supply Ventana and of
each Software

                                       1
<PAGE>   2

Product. Alpha Testing shall consist of Ventana's testing with assistance from
AccuMed of the performance of a product against a performance protocol to be
established by Ventana under this Agreement where such testing may be done
in-house at either Ventana's and/or AccuMed's facilities as Ventana may decide
in its sole discretion. A product shall be considered to have passed Alpha
Testing if it performs to the performance protocol as demonstrated to Ventana's
reasonable satisfaction.

               "Basic Imaging and Report Generation Product" shall mean a
software product for capturing an image of tissue mounted on a microscope slide,
manipulating the image, and preparing a report to Ventana's specifications as
will be more fully described in the Marketing Specifications.

               "Beta Testing" shall mean the beta testing of Manufacturing
Prototypes to a performance protocol established by Ventana in Ventana customer
labs as selected by Ventana for a period determined by Ventana in its sole
discretion. A product will be considered to have passed Beta Testing if it
performs to the performance protocol in all customer labs selected by Ventana
for Beta Testing.

               "Breast Cancer Panel" shall mean [***]software products for
performing quantitated immunohistochemistry (QIHC) on patient breast cancer
slides stained for estrogen receptor, progesterone receptor, proliferation
receptor (as measured using either Ki-67 or MIB-1 antibodies) and her-2/neu
receptor as will be more fully described in the Marketing Specifications.

               "Developed Software" shall mean all software and related
documentation developed by AccuMed for Ventana under this Agreement and any
updates made thereto.

               "Development Plan" and "Development Schedule" will mean,
respectively, a plan and schedule designated as such in Section 6.1.

               "Direct Costs" shall mean personnel, supplies, materials, and
contracted and outside services costs attributable to the materials or for the
production of an item.

               "Effective Date" is defined in the preamble to the Agreement.

               "Engineering Prototypes" shall mean fully developed hardware or
software products related to the Imaging System to be delivered to Ventana that
have not yet passed Alpha Testing.

               "Excluded Field" shall mean but not limited to: [***] Excluded
Field shall not extend to Ventana's Medical Research Sales and Internal Research
and Development.

               "FDA Approval" shall have the meaning specified in Section 9.1.6.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       2
<PAGE>   3

               "Field"  [***]  Field shall exclude the Excluded Field.

               "Field Exclusivity" shall mean the rights granted to Ventana and
the restrictions on AccuMed as specified in Section 5.1.

               "Foreground Technology" shall have the meaning specified in
Section 3.1.

               "Functional Specifications" shall mean a detailed engineering
specification that is in accordance with the Marketing Specifications and which
will be used by software and hardware engineers to develop the Imaging System
and Software Products.

               "Imaging System" shall mean an automated pathology imaging system
based on AccuMed's existing AcCell 2001 workstation and to be further developed
by AccuMed in conformance with the Functional Specifications and improvements
made thereto by either party during the term of this Agreement. The Imaging
System includes but is not limited to certain basic software used in the
operation of the Imaging System.

               "Installations" shall have the meaning specified in Section 7.4.

               "Internal Research and Development" shall mean the internal use
of Imaging Systems by employees and contractors of a party to this Agreement
only for research and development.

               "Maintenance" shall have the meaning specified in Section 7.4.

               "Manufacturing Prototypes" shall mean the initial manufacturing
prototypes of the Imaging System and each Software Product manufactured or made
by AccuMed to be delivered to Ventana for Beta Testing in Ventana customer labs.

               "Manufactured Product" shall mean each Imaging System
manufactured and sold by AccuMed to Ventana hereunder.

               "Marketing Specifications" shall mean a detailed specification of
the performance requirements for the Imaging System and the Software Products
prepared by Ventana and will be an expanded version of the specifications
contained in Exhibit 1-2.

               "Master Validation Protocol" shall mean a master validation
protocol used by Ventana to seek FDA 510k approval from the U.S. Food and Drug
Administration for the Imaging System and Software Products.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       3
<PAGE>   4

               "Medical Research Sales" shall mean the sale by or under the
authority of a party to this Agreement of Imaging Systems to end customers only
for their internal medical research purposes, and expressly excludes the use or
sale of such Imaging Systems for: (i) any commercial use or gain by any such end
customers, (ii) any commercial use in the direct or indirect treatment of
patients, or (iii) any resale or further distribution by such end customers.

               "Payment Report" shall mean a report designated as such in
Section 9.5.3.

               "Ploidy Product" shall mean a software product to be developed by
AccuMed for Ventana for conducting DNA ploidy analysis as will be more fully
described in the Marketing Specifications.

               "Product Exclusivity" shall mean the exclusivity of the licenses
granted to Ventana in Article 2.

               "Products" shall mean any medical products and systems, including
but not limited to the [***] Products shall also include any subsequent hardware
and software products developed by AccuMed for Ventana under this Agreement.

               "Proprietary Information" shall have the meaning specified in
Section 4.1.

               "Rare Event Detection Product" shall mean a software product to
be developed by AccuMed for Ventana that will permit Ventana [***] The FDA
labeling that Ventana will be seeking and the protocol that will be required by
the FDA to obtain this label is referenced in Exhibit 1-4.

               "Royalty Product" shall mean an Imaging System manufactured and
sold by or under the authority of Ventana. Royalty Product shall exclude any
Manufactured Product.

               "Subsidiaries" shall mean any legal entity more than or equal to
fifty percent (50%) of whose outstanding shares or securities (representing the
right to vote for the election of directors or other managing authority) are,
now or hereafter, owned or controlled, directly or indirectly by a party.

               "Software Products" shall mean any software product developed or
customized for Ventana under this Agreement, including but not limited to the
[***]

               "Source Code" shall mean all source code and documentation for
the Software Products and any other software related to or used with any Imaging
System, and updates to all of the foregoing during the term of this Agreement.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       4
<PAGE>   5

               "Technology Transfer" shall mean the transfer of AccuMed
Intellectual Property Rights embodied in tangible form, including copies of any
issued patents and pending patent applications, to Ventana as set forth in
Article 8.

               "Telepathology Product" shall mean[***]

2.      Grant of LicenseS.

        2.1 Subject to the terms and conditions of this Agreement, AccuMed
hereby grants to Ventana and its Subsidiaries a perpetual, irrevocable,
worldwide, royalty-free (except as otherwise provided to be royalty-bearing
hereunder) license under AccuMed Patent Rights and AccuMed Technical Information
to use, make, have made, import, offer to sell and sell Products and to practice
any process or method involved in the manufacture or use of Products. The
foregoing license shall be (i) exclusive in the Field (even as against AccuMed
except as provided in Section 2.4 below) and non-exclusive outside the Field,
provided that such non-exclusive license shall not extend to the Excluded Field;
and (ii) sublicensable with AccuMed's written approval, which shall not be
unreasonably withheld.

        2.2 Subject to the terms and conditions of this Agreement, AccuMed
hereby grants to Ventana and its Subsidiaries a sublicensable, perpetual,
irrevocable, worldwide, royalty-free (except as otherwise provided to be
royalty-bearing hereunder) license under AccuMed Intellectual Property Rights to
use, reproduce, distribute (directly or indirectly through one or more levels of
distribution), modify, adapt, and create derivative works of the AccuMed
Software (including any modifications and derivative works thereof made by
Ventana) and to otherwise utilize the AccuMed Software in the manufacture, sale,
or design of Products; provided that the AccuMed Software and modifications and
derivative works thereof may be distributed only in source and object code form
integrated into or bundled with Products or as updates of the AccuMed Software
provided to end-user customers of Products. The foregoing license shall be (i)
exclusive in the Field (even as against AccuMed) and non-exclusive outside the
Field, provided that such non-exclusive license shall not extend to the Excluded
Field; and (ii) sublicensable with AccuMed's written approval, which shall not
be unreasonably withheld.

               2.2.1 With respect only to Source Code owned by AccuMed, the
foregoing license shall be limited to the maintenance, support, and continued
development of the Software Products and any other software related to or useful
with the Imaging System.

        2.3 License Grant-Back. Subject to the terms and conditions of this
Agreement and during the term hereof, Ventana hereby grants to AccuMed a
non-exclusive, worldwide, non-sublicensable, royalty-free license, but only
outside of the

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       5
<PAGE>   6

Field, to use, reproduce, distribute, modify, adapt, and create derivative works
of the Developed Software; provided that the Developed Software may be
distributed only in source and object code form under the terms of an End-User
Software License reasonably acceptable to and approved in advance in writing by
Ventana.

        2.4 Reservation. The license granted in Section 2.1 above is subject to
a reserved worldwide non-exclusive license in the Field to AccuMed solely for
Internal Research and Development and Medical Research Sales, subject to
AccuMed's obtaining a written agreement from end customers of Medical Research
Sales that any Imaging Systems sold are not licensed for commercial use by
others in the direct or indirect treatment of patients and shall not be resold
or further distributed.

        2.5 Improvements. Any AccuMed modifications or improvements to the
AccuMed Software or Imaging System made before the termination of this Agreement
shall be included in the licenses of this Article 2 without additional charge to
Ventana. AccuMed agrees to promptly disclose such modifications and
improvements. To assist in the transfer of modifications and improvements,
Ventana shall be entitled to have a development engineer observe the operations
of AccuMed related to the subject matter of the licenses of this Article 2 for
up to one month per year during the term of this Agreement.

3.      OWNERSHIP.

        3.1 Ownership. Ventana shall exclusively own all right, title and
interest (including patent rights, copyrights, trade secret rights, mask work
rights and all other intellectual and industrial property rights of any sort
throughout the world) in any inventions, works of authorship, mask works, ideas
or information made or conceived or reduced to practice by AccuMed in the course
of performance under this Agreement (the "Foreground Technology"), which course
of performance shall include without limitation the initial and future
development of the Imaging System and Software Products or any maintenance
provided by AccuMed hereunder as part of this Agreement. However, Ventana shall
have no ownership of any Developer Stock. "Developer Stock" shall mean AccuMed's
preexisting software engines, development tools and routines, as well as
derivatives and modifications thereof; provided that if any such derivative or
modification is made in the course of performance under this Agreement, then it
will qualify as Developer Stock only if it (i) has substantially the same
functionality as other Developer Stock and (ii) has general applicability apart
from the Software Products.

               3.1.1 AccuMed may use third party software in the software to be
delivered to Ventana under this Agreement; provided that (i) Ventana obtains the
rights from such third parties necessary to provide all rights granted to
Ventana under this Agreement and (ii) AccuMed obtains such third party software
at AccuMed's sole expense. Notwithstanding the foregoing, Ventana shall be
responsible for obtaining a license for the software to be used in the
Telepathology Product. If AccuMed uses Accumed or third party software or data
in any software or other materials to be delivered to Ventana under this
Agreement, AccuMed shall identify the software modules

                                       6
<PAGE>   7

containing AccuMed Software and separately identify the modules containing third
party software at the time of delivery to Ventana.

        3.2 AccuMed hereby makes and agrees to make any assignments necessary to
accomplish the foregoing ownership provisions. In interpreting such ownership
provisions anything made or conceived or reduced to practice by an employee or
contractor of AccuMed in the course of performance under this Agreement will be
deemed so made or conceived or reduced to practice by that party; AccuMed has
and will have appropriate agreements with all such employees and contractors
necessary to fully effect the provisions of this Article 3.

        3.3 Ventana will have the exclusive right to, and, at Ventana's expense,
AccuMed agrees to assist Ventana in every proper way (including, without
limitation, becoming a nominal party) to, evidence, record and perfect the
foregoing assignments and to apply for and obtain recordation of and from time
to time enforce, maintain, and defend any proprietary right assigned to Ventana
under this Agreement. AccuMed will execute all documents Ventana may reasonably
request for such purposes.

        3.4 Any assignment by AccuMed of copyright hereunder includes all rights
of paternity, integrity, disclosure and withdrawal and any other rights that may
be known as or referred to as "moral rights" (collectively "Moral Rights"). To
the extent such Moral Rights cannot be assigned under applicable law and to the
extent the following is allowed by the laws in the various countries where Moral
Rights exist, AccuMed hereby ratifies and consents to any action consistent with
the terms of this Agreement that would violate such Moral Rights in the absence
of such ratification/consent. AccuMed will confirm any such ratifications and
consents from time to time as requested by Ventana.

4.      Confidential Information.

        4.1 Confidentiality. Each party agrees that all inventions, processes,
materials, chemicals, know-how and ideas and all other business, technical and
financial information they obtain from the other are the confidential property
of the disclosing party ("Proprietary Information" of the disclosing party).
Except as expressly allowed in this Agreement, the receiving party will hold in
confidence and not use or disclose any Proprietary Information of the disclosing
party and shall similarly bind its employees in writing. The receiving party
shall not be obligated under this Section 4.1: (i) beyond five years after
termination of this Agreement or (ii) with respect to information the receiving
party can document:

               (a) is or has become readily publicly available through no fault
of the receiving party or its employees or agents; or

               (b) is received from a third party lawfully in possession of such
information and lawfully empowered to disclose such information and provided the
receiving party abides by all restrictions imposed by such third party; or

                                       7
<PAGE>   8

               (c) was rightfully in the possession of the receiving party prior
to its disclosure by the other party provided the receiving party abides by all
restrictions imposed on its possession of such information; or

               (d) was independently developed by employees or consultants of
the receiving party without access to such Proprietary Information.

5.      field Exclusivity.

        5.1 Neither AccuMed nor any Subsidiary shall develop, manufacture,
purchase, distribute, or market anywhere worldwide during the term of this
Agreement (or have or enter into any agreement or arrangement with respect to)
any product or system: (i) competitive with or substantially similar to the
Imaging System or Software Products or (ii) in the Field.

        5.2 Termination of Field Exclusivity shall have no effect on Product
Exclusivity under the licenses granted to Ventana under Article 2.

6.      PRODUCT DEVELOPMENT.

        6.1 Imaging System and Software Product Specifications. With respect to
the Imaging System and the Software Products, AccuMed shall, within [***]of
receiving the Marketing Specifications, complete the Functional Specifications
and a development plan and schedule consistent with the Marketing Specifications
("Development Plan" and "Development Schedule") for the Imaging System and the
Software Products. Ventana agrees to consult with and assist AccuMed in doing so
including but not limited to providing AccuMed's development engineers with
ongoing assistance by Ventana's medical experts as reasonably necessary to
develop the Software Products with functionality consistent with the Functional
Specifications and Ventana's intended customer markets. The completed Functional
Specifications and Development Plan and changes thereto are subject to the
approval of Ventana, which approval shall not be unreasonably withheld.

        6.2 AccuMed's Development Obligations. For the Imaging System and
Software Products, AccuMed will perform the following activities consistent with
the Functional Specifications, Development Plan, and Development Schedule: (i)
undertake and complete development of the Imaging System and Software Products
as set forth in the completed Functional Specifications, including manufacturing
scale-up, (ii) prepare and provide Ventana with development information for the
Imaging System and Software Products as necessary or reasonably desirable for
any regulatory filings, (iii) assist with Alpha Testing and Beta Testing of the
Imaging System and Software Products as set forth herein, and (iv) deliver the
Engineering Prototypes and Manufacturing Prototypes to Ventana.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       8
<PAGE>   9

               6.2.1 Within [***] of the Effective Date, AccuMed shall deliver
to Ventana a first Engineering Prototype of the Imaging System and an
Engineering Prototype of the Rare Event Detection Product (each in a form
suitable for conducting FDA clinical trials).

               6.2.2 Within [***] of the Effective Date, AccuMed shall deliver a
second Engineering Prototype of the Imaging System and Engineering Prototypes of
the [***].

               6.2.3 Within [***] of the Effective Date, AccuMed shall deliver
the Engineering Prototype for the [***].

               6.2.4 AccuMed shall deliver [***] Manufacturing Prototypes of the
Imaging System and [***] copies of each of the [***]

               6.2.5 AccuMed shall deliver [***] Manufacturing Prototypes of the
[***] to Ventana for Beta Testing within 10 days of the completion of Alpha
Testing thereof.

               6.2.6 Telepathology Product. AccuMed shall assist Ventana in its
search for and selection of a third party vendor for a software product suitable
for customization by AccuMed to deliver the Telepathology Product under this
Agreement. AccuMed or its contractors shall perform customization to such
vendor's product as necessary to ensure compliance with the Functional
Specifications and the compatibility and interoperability of the Telepathology
Product with the Imaging System and other Software Products and the manner of
Ventana's intended use thereof. AccuMed shall deliver an Engineering Prototype
and a Manufacturing Prototype of the Telepathology Product to Ventana on
reasonable successive dates consistent with other delivery dates hereunder and
as mutually agreed by the parties.

        6.3    Ventana's Development Obligations.

               6.3.1 Ventana shall provide AccuMed with the Marketing
Specifications within 15 days after the Effective Date for AccuMed's use in
preparing the Functional Specifications.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       9
<PAGE>   10

               6.3.2 Ventana shall complete Alpha Testing for the first
Engineering Prototype of the Imaging System and the Engineering Prototype of the
[***]to be delivered under Section 6.2.1 within [***]of the receipt thereof.

               6.3.3 Ventana shall complete Alpha Testing for the second
Engineering Prototype of the Imaging System and the Engineering Prototypes of
the [***]to be delivered under Section 6.2.2 within [***]of the receipt thereof.

               6.3.4 Ventana shall complete Beta Testing for the Manufacturing
Prototypes of the Imaging System, the [***]to be delivered under Section 6.2.4
within [***]of the receipt thereof.

               6.3.5 Ventana shall complete Alpha Testing for the Engineering
Prototype of the [***]to be delivered under Section 6.2.3 within [***]of the
receipt thereof.

               6.3.6 Ventana shall complete Beta Testing for the Manufacturing
Prototype of the [***]to be delivered under Section 6.2.5 within [***]of the
receipt thereof.

               6.3.7 Ventana may in its sole discretion and at its expense
obtain any regulatory approvals necessary for Ventana's manufacturing, sales,
marketing, and service of the Imaging System, including but not limited to any
beta testing of the Manufacturing Prototypes by Ventana. Ventana's obligations
hereunder shall include, without limitation, all testing and other activity
necessary or useful to ensure compliance with applicable governmental or
administrative rules and regulations. Ventana shall be entitled to submit the
filings in its name.

               6.3.8 Ventana shall commence FDA clinical trials for the Master
Validation Protocol within [***]after the completion of Alpha Testing for the
first Engineering Prototype of the Imaging System and the Engineering Prototype
of the [***]with an expectation of FDA clearance within [***]of the Effective
Date, assuming the Rare Event Detection Product is delivered by AccuMed on time
as provided hereunder and passes Alpha Testing within [***]of receipt by
Ventana.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       10
<PAGE>   11

        6.4    Acceptance.

               6.4.1 Acceptance of Deliverables. All deliverables provided by
AccuMed under this Agreement shall be delivered for Ventana's acceptance testing
in accordance with the acceptance procedure set forth in Section 6.4.2 below.
Prior to each delivery, AccuMed shall have completed all required testing
applicable to such deliverables to ensure material compliance with the
applicable specifications hereunder.

               6.4.2  Acceptance Testing.

               (a) Acceptance Standards. Following receipt of each deliverable,
including but not limited to any deliverables intended for Alpha Testing or Beta
Testing, Ventana shall have the time period for testing as set forth under this
Agreement, or if not otherwise set forth herein for any deliverable, a time
period of 30 days (the "Verification Period") in which to use commercially
reasonable efforts to review, examine and verify such deliverable and notify
AccuMed of either: (a) any material failure thereof as determined by Ventana to
meet the applicable specifications, or (b) any other rejection for technical
reasons by Ventana as determined in its reasonable sole discretion (a
"Failure").

               (b) Beta Testing. Any deliverable subject to Beta Testing
hereunder shall also be subject to technical acceptance by Ventana's selected
beta site customers. Such technical acceptance shall be determined by such
customer in its sole reasonable discretion. Such technical acceptance shall be
communicated to AccuMed by Ventana and shall be subject to the time limit for
the Verification Period above and the Acceptance Procedure set forth in
subsection (c) below.

               (c) Acceptance Procedure. If Ventana discovers any Failure, it
shall promptly provide AccuMed with written notice of such Failure, including
all information reasonably available regarding such Failure. Upon receipt of
such notice, AccuMed shall use its best efforts, at AccuMed's sole cost and
expense, to correct any such Failure and to resubmit the corrected applicable
deliverables to Ventana as soon as commercially and technically practicable, but
in all events within 21 days following Ventana's notification of a Failure.
AccuMed shall repeat the process of correction and resubmission of the
applicable deliverable, subject to additional Verification Periods, until
Ventana's acceptance. The parties agree that any failure by Ventana to discover
and notify AccuMed of defects within any Verification Period shall not negate
any of AccuMed's representations or warranties, nor waive any of Ventana's
rights or remedies hereunder.

        6.5 Future Development. AccuMed shall develop any improvements to the
Imaging System and Software Products as may be reasonably requested in writing
by Ventana from time to time during the term of this Agreement for Ventana's
continued expansion of its products sales and services and the continuing
introduction of new product features. Such requests may include but not be
limited to modifications to the

                                       11
<PAGE>   12

initial Imaging System hardware platform, the development of a totally new,
higher throughput imaging system for larger labs, modifications to existing
software modules, and the development of completely new software modules for use
with existing or future imaging systems. Such development under this Section 6.5
shall be pursuant to specifications developed by Ventana with the cooperation of
AccuMed. Ventana shall pay AccuMed for such development work at an additional
development cost as mutually agreed by the parties.

7.      SUPPLY AND MARKETING.

        7.1 AccuMed's Supply Obligations. AccuMed shall manufacture and deliver
those quantities of Manufactured Product as specified below, FOB AccuMed's
plant. Manufactured Products delivered by AccuMed shall incorporate the latest
improvements to the Imaging System developed by AccuMed hereunder or otherwise
at no additional cost to Ventana, including but not limited to any such
improvements related to Maintenance. Each Manufactured Product shall include
without limitation all specified hardware and the Basic Imaging and Report
Generating Product.

        7.2    Quantity.

               7.2.1 AccuMed will manufacture and deliver [***] Manufactured
Products to Ventana with delivery at a rate of [***] Manufactured Products per
calendar quarter commencing with the first full calendar quarter following the
completion of Beta Testing for the Imaging System and all Software Products and
receipt by Ventana of FDA Approval. Delivery of such Manufactured Products may
be accelerated with mutual agreement. Each Manufactured Product will be
delivered with the AccuMed Software and/or Software Products as specified in
Ventana's sole discretion.

               7.2.2 If AccuMed fails to ship at least 75% of the amount of any
Manufactured Product for a given calendar quarter as required above, (a "Supply
Deficiency"), Ventana may so notify AccuMed in writing whereby: (i) Technology
Transfer will be accelerated as necessary to permit the immediate manufacture of
Imaging Systems by Ventana, and (ii) AccuMed will promptly prepare a plan as to
how to remedy the situation (which may involve new or expanded production
facilities or a third party producer). AccuMed will use diligent efforts to
implement such plan and shall provide Ventana with quarterly reports on its
progress. If such plan is not substantially implemented within 2 months from
Ventana's notice (and it will not be substantially implemented in significantly
less time than Ventana could begin commercial production thereafter) (an
"Implementation Failure"), then AccuMed will provide Ventana with all technical
assistance reasonably necessary for Ventana to make and have made such
Manufactured Products to meet the portion of Ventana's requirements of that
Manufactured Product that AccuMed cannot supply hereunder, for which such
portion of Manufactured Products shall not be subject to a royalty as

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       12
<PAGE>   13

otherwise provided hereunder. In addition to the foregoing rights, in the event
of a Supply Deficiency, Ventana shall have the right to terminate any further
obligation to purchase Manufactured Products effective immediately upon
providing written notice to AccuMed.

        7.3 Ventana's Marketing Obligations. Ventana represents, warrants and
agrees:

               7.3.1 to comply with all export laws and restrictions and
regulations of the Department of Commerce or other United States or foreign
agency or authority, and not to export, or allow the export or reexport of any
Proprietary Information of AccuMed or any product thereof in violation of any
such restrictions, laws or regulations.

               7.3.2 in addition to and without in any way limiting Ventana's
other obligations hereunder, to use all methods to protect the parties' rights
with respect to the Proprietary Information of AccuMed as it uses to protect its
own or any third party's confidential information or intellectual property
rights.

        7.4 Maintenance. AccuMed shall provide maintenance services (including
but not limited to engineering and testing work) for the correction of defects
or errors and the development of improvements for all Manufactured Products and
Royalty Products or any other deliverables sold or provided to Ventana under
this Agreement (the "Maintenance"); provided that Ventana shall be responsible
for the actual installation and retrofitting (the "Installations") of software
upgrades or hardware improvements for any Manufactured Products and Royalty
Products that have been installed for use in a Ventana facility or purchased by
any other third party.

               7.4.1. Maintenance shall include but not be limited to prompt
correction of any software errors and any hardware defects in any deliverables
provided to Ventana hereunder and AccuMed shall provide all personnel and bear
any and all expenses, travel or otherwise, as required as part of Maintenance
except for Installations. AccuMed shall commit at least one full-time equivalent
employee for providing Maintenance. Maintenance shall further include the
providing of all updates to any software and all improvements to any hardware
for any deliverables that have been provided to Ventana hereunder.

               7.4.2 All software and hardware upgrades and improvements shall
be delivered to Ventana as part of Maintenance at no additional cost to Ventana,
except that Ventana shall pay AccuMed [***]for any hardware parts provided as
part of Maintenance that provide an improvement in performance other than due to
an error or defect correction.

               7.4.3 During the term of this Agreement and as payment for the
Maintenance, Ventana shall pay AccuMed a maintenance fee of U.S. [***]with the
first

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       13
<PAGE>   14

such installment commencing on the first day of the first month of the first
full calendar quarter following receipt by Ventana of FDA Approval and
completion of Beta Testing for the Imaging System and all Software Products.
Ventana may discontinue Maintenance at any time with written 90-day notice.

        7.5 Ventana shall purchase parts from AccuMed's current parts inventory:
(i) as required for the replacement of parts for the Manufactured Products
installed for end-use at any Ventana facility, and (ii) as needed by Ventana for
its manufacture of any Royalty Products; provided that the foregoing obligation
(a) shall only apply for those Manufactured Products or Royalty Products using
the AcCell 2001 hardware platform (and only for such parts that are usable), and
(b) shall not apply to any parts added to AccuMed's inventory after the
Effective Date. AccuMed shall provide a full written inventory list of such
parts and AccuMed's Direct Costs for each part to Ventana within 60 days of the
Effective Date. AccuMed shall internally identify and track such parts in its
inventory, and report such information to Ventana from time to time as
reasonably requested by Ventana, to assist Ventana in determining the extent of
its purchase obligation under this Section 7.5. Any parts purchased by Ventana
under this Section 7.5 shall be at AccuMed's[***]; provided that with respect to
parts purchased for Royalty Products, in no event will Ventana's total costs for
such parts per Royalty Product exceed $15,000. The obligations of this Section
7.5 shall not apply to any sublicensees of Ventana.

8.      TECHNOLOGY TRANSFER.

        8.1 Transfer of Technology. To carry on the physical transfer of AccuMed
Technical Information from AccuMed to Ventana, AccuMed shall provide to Ventana
as soon as reasonably practicable after the Effective Date all AccuMed
Intellectual Property Rights embodied in tangible form as is reasonably
necessary for Ventana to be ready to begin manufacture and continue development
of the Imaging System and the Software Products (including but not limited to
the Source Code, all related object code and documentation, and any other
related information) beginning on the earlier of: (i) one year after the
Effective Date or (ii) the completion of delivery of [***] Manufactured Products
to Ventana.

               8.1.1 AccuMed shall further promptly disclose and transfer to
AccuMed on a monthly basis all Foreground Technology.

        8.2 Technical Assistance. During the term of this Agreement, AccuMed
shall provide ongoing technical assistance by qualified AccuMed employees at
Ventana's site as necessary to transfer manufacturing capability for
Manufactured Products to Ventana and to support Ventana's ongoing manufacturing
and development efforts related to the Imaging System. Ventana shall pay
reasonable travel and lodging expenses to AccuMed

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       14
<PAGE>   15

for such technical assistance; provided such travel is approved in advance in
writing by Ventana.

        8.3 Source Code. AccuMed shall deliver the Source Code to Ventana as
soon as reasonably practicable after the Effective Date and shall deliver
updates of the Source Code to Ventana on a quarterly basis thereafter.

9.      PAYMENTS.

        9.1 Development Funds. Ventana shall pay to AccuMed a total fee of U.S.
[***]for all development of the Imaging System and the delivery of the
Engineering Prototypes (including but not limited to all related software) under
this Agreement payable in installments as follows (the "Development Funds"):

               9.1.1 Upon the execution of this Agreement by both parties,
Ventana shall pay [***] to AccuMed.

               9.1.2 Upon completion of Alpha Testing and Ventana's acceptance
of the Engineering Prototypes for the Imaging System and the[***], Ventana shall
pay [***] to AccuMed.

               9.1.3 Upon completion of Alpha Testing and Ventana's acceptance
of the Engineering Prototypes for the[***], Ventana shall pay [***] to AccuMed.

               9.1.4 Upon completion of Beta Testing and acceptance by Ventana
and Ventana's beta site customers of the Engineering Prototypes for the Imaging
System, the[***], Ventana shall pay [***] to AccuMed.

               9.1.5 Upon completion of Beta Testing and Ventana's acceptance of
the Engineering Prototype for the[***], Ventana shall pay [***] to AccuMed.

               9.1.6 Upon the U.S. FDA issuing to Ventana a letter of
approvability of a Master Validation Protocol that is a 510k equivalent to that
obtained by [***]("FDA Approval"), Ventana shall pay [***] to AccuMed.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       15
<PAGE>   16

        9.2 Use of Development Funds. AccuMed shall hold and use the Development
Funds solely for the purpose of applying to AccuMed's direct and indirect
development costs under this Agreement until the completion of Beta Testing,
after which the foregoing restriction shall no longer apply.

        9.3 Manufacturing Prototype Pricing. In addition to the Development
Funds, Ventana shall pay AccuMed U.S. [***]for each Manufacturing Prototype of
the Imaging System delivered to and accepted by Ventana hereunder. No payment
shall be due for any Manufacturing Prototypes of the Software Products.

        9.4 Manufactured Product Pricing. In connection with the supply of
Manufactured Products, Ventana shall pay AccuMed U.S. [***]for each Manufactured
Product of the Imaging System delivered to and accepted by Ventana hereunder.
Except as set forth in Section 9.5 below, no payment shall be due for any
Software Products delivered with a Manufactured Product.

        9.5 Royalties. Ventana will pay a royalty to AccuMed on the sale of each
Royalty Product and those software products set forth below by or under the
authority of Ventana; provided that no royalty shall be due for any Manufactured
Product purchased from Ventana or any bona fide sample and clinical trial
products or copies of software.

               9.5.1 Royalty Amounts. The royalty shall be U.S. [***]for each
Royalty Product sold.

               9.5.2 Software Products. In addition to the payment of a royalty
        for each Royalty Product, Ventana shall pay an additional royalty to
        AccuMed for each of the following listed software products integrated
        into or bundled with either: (i) a Manufactured Product purchased from
        AccuMed, or (ii) a Royalty Product manufactured and sold by Ventana;
        provided that in no event shall any royalty be due for any such software
        product obtained or licensed by Ventana from a third party (including
        but not limited to the Telepathology Product). No royalty shall be due
        for other Software Products not listed below. The royalty rates for
        software products under this Section 9.5.2 shall be as follows:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------
              PRODUCT                         ADDITIONAL ROYALTY PER
                                                  IMAGING SYSTEM
-------------------------------------------------------------------------------
<S>                                 <C>
[***]                               [***]
-------------------------------------------------------------------------------
[***]                               [***]
-------------------------------------------------------------------------------
</TABLE>

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       16
<PAGE>   17

               9.5.3 Payment Report. With each payment of royalties, Ventana
shall provide AccuMed with a report delineating: (a) the number and types of
Royalty Products sold during the applicable period, and (b) the calculation of
the amount due (the "Payment Report").

               9.5.4 Payment Terms. Royalties for sales of Royalty Product will
be due within sixty (60) days of the end of each calendar quarter with respect
to sales of Royalty Product recognized or received in such period. Royalties for
software products under Section 9.5.2 above are due at the same time as
royalties for the corresponding Royalty Product in which such software products
have been installed or in the calendar quarter of installation, if installed
later.

               9.5.5 Records and Audit Rights. Ventana shall keep complete and
accurate records reflecting all information necessary or useful in verifying the
accuracy of each Payment Report. AccuMed shall have the right to hire an
independent certified public accountant to inspect all such records so required
to be kept by Ventana (which accountant shall agree in writing to keep all
information confidential except as needed to disclose any discovered
discrepancies to AccuMed); provided such audit: (i) is conducted during normal
business hours, (ii) is conducted no more often then once per year (unless a
discrepancy is discovered in favor of AccuMed), and (iii) is conducted only
after AccuMed has given thirty days prior written notice. AccuMed shall bear the
full cost and expense of such audit, unless AccuMed discovers a discrepancy of
more than 1% in which case such cost and expense shall be equally shared.

        9.6 Up-Front License Fee Payments. Upon the execution of this Agreement
by both parties and as partial consideration for the license grants hereunder,
Ventana shall pay AccuMed: (i) an up-front non-creditable fee of[***], and (ii)
an additional up-front fee of [***] to be creditable against future royalties
due hereunder by Ventana.

10.     LIMITED LIABILITY.

        NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER
PARTY WILL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS
AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES.

11.     TERM AND TERMINATION.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       17
<PAGE>   18

        11.1 Term. This Agreement will remain in effect for [***] years with
automatic [***]-year renewals unless either party gives written notice 180 days
prior to the end of the then current term not to renew or unless terminated
pursuant to Section 11.2.

        11.2 Termination. This Agreement may be terminated in its entirety by a
party for cause immediately upon the occurrence of any of the following events:

               (a) If the other ceases to do business, or otherwise terminates
its business operations;

               (b) If the other materially breaches any provision of this
Agreement and fails to cure such breach within sixty (60) days of written notice
describing the breach; or

               (c) If the other shall seek protection under any bankruptcy,
receivership, trust deed, creditors arrangement, composition or comparable
proceeding, or if any such proceeding is instituted against the other (and not
dismissed within one hundred and twenty (120) days).

        11.3 Liability Disclaimer. Neither party shall incur any liability
whatsoever for any damage, loss or expenses of any kind suffered or incurred by
the other (or for any compensation to the other) arising from or incident to any
termination of this Agreement by such party which complies with the terms of the
Agreement whether or not such party is aware of any such damage, loss or
expenses.

        11.4 Effect of Termination. For any expiration or termination of this
Agreement, the following provisions shall survive: Sections 2.1, 2.2, 2.3, 2.4,
3, 4, 9.5, 10, 12, 13, and 15 and any other Sections as necessary for Ventana to
fully exploit its licenses under Article 2. Remedies for breaches will also
survive. Each party will promptly return all Proprietary Information of the
other (and all copies and abstracts thereof) that it is not entitled to use
under the surviving terms of this Agreement; provided that Ventana may retain
all Source Code and object code and documentation for the Software Products, all
information transferred by AccuMed as part of Technology Transfer, and any other
information received by Ventana hereunder that Ventana reasonably believes
necessary or desirable for exploitation of its licenses under Article 2.

        11.5 Termination Not Sole Remedy. Termination is not the sole remedy
under this Agreement and, whether or not termination is effected, all other
remedies will remain available.

12.     WARRANTY AND WARRANTY DISCLAIMERS.

---------------

[***] Confidential treatment has been requested for the bracketed portion. The
confidential redacted portion has been omitted and filed separately with the
Securities and Exchange Commission.

                                       18
<PAGE>   19

        12.1 AccuMed hereby represents, warrants, and covenants to Ventana as
follows:

               12.1.1 The Engineering Prototypes, the Manufacturing Prototypes,
and the Manufactured Products and the Software Products will conform to the
applicable Functional Specifications, as then in effect, and any published
AccuMed documentation related thereto. Such warranty does not apply to units
that have been mishandled or mistreated.

               12.1.2 AccuMed and its Subsidiaries are the sole owner of the
patents and patent applications listed in Exhibit 1-1 and there are no other
patents issued and no other patent applications filed in any country worldwide,
in each case owned or filed by or specifically licensed to AccuMed or any of its
Subsidiaries relating to the Imaging System or the Software Products or methods
of use or the manufacture thereof.

               12.1.3 AccuMed has not granted any third party any rights or
interests to any AccuMed Intellectual Property Rights relating to the Imaging
System or the Software Products.

               12.1.4 AccuMed is not aware of any actual or potential violation,
infringement or misappropriation of any third party's rights (or any claim or
potential claim thereof) by any of the deliverables to be provided by AccuMed
hereunder (or inherent in the development, use or production thereof).

               12.1.5 AccuMed has full power and authority to enter into and
perform this Agreement.

               12.1.6 Neither AccuMed's entering nor performing this Agreement
will violate any right of or breach any obligation to any third party under any
agreement or arrangement between AccuMed and such third party.

        12.2 EXCEPT FOR THE FOREGOING WARRANTY OF SECTION 12.1.1, ACCUMED DOES
NOT WARRANT THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY UNITS
DELIVERED TO VENTANA UNDER THIS AGREEMENT.

13. INDEMNITY. AccuMed shall hold Ventana and its officers, directors, agents
and employees harmless from liability resulting from infringement by the Imaging
System, the Software Products, or any other Products using parts, software, or
technical information provided by AccuMed of any patent, copyright, trade
secret, or other intellectual property right, provided AccuMed is promptly
notified of any and all threats, claims and proceedings related thereto and
given reasonable assistance and the opportunity to assume sole control over the
defense and all negotiations for a settlement or compromise; AccuMed will not be
responsible for any settlement it does not approve in writing. The foregoing
obligation of AccuMed does not apply with respect to any parts, software, or
technical information: (i) not supplied by AccuMed, (ii) to the extent

                                       19
<PAGE>   20

such infringement arises from Ventana's specifications, (iii) which are modified
by Ventana after shipment by AccuMed, to the extent the alleged infringement
relates to such modification, (iv) combined, processed or used with other
products, processes or materials where the alleged infringement relates to such
combination, process or use, or (v) where the infringement is incident to use of
the Product but does not result primarily from the Product.

14. RIGHT OF NOTIFICATION. AccuMed shall notify Ventana in writing within 3 days
following the date on which any of the following occur: (i) AccuMed receives
from any person or entity a bona fide solicitation, proposal or offer with
respect to the merger or consolidation, purchase of common stock or securities
convertible into common stock of AccuMed exceeding 10% of AccuMed's then
outstanding common stock (on a fully diluted basis), or acquisition of assets
(other than inventory and excluding the license of assets) outside the ordinary
course of business, or similar transaction or business combination involving
AccuMed, or (ii) AccuMed determines (through its board of directors or
otherwise) to solicit, initiate, or participate in any discussions or
negotiations regarding, furnish any information with respect to, assist or
participate or facilitate in any other manner any effort or attempt by any other
person to do or seek any of the transactions described in subsection (i) above.
During the 20 day period beginning on the date of any such notice to Ventana,
AccuMed shall not enter into binding agreement to complete such transaction, and
shall not enter into any no-shop or standstill agreements with any person with
respect to such transaction.

15.     GENERAL.

        15.1 Amendment and Waiver. Except as otherwise expressly provided
herein, any provision of this Agreement may be amended and the observance of any
provision of this Agreement may be waived (either generally or in any particular
instance and either retroactively or prospectively) only with the written
consent of the parties. However, it is the intention of the parties that this
Agreement be controlling over additional or different terms of any purchase
order, confirmation, invoice or similar document, even if accepted in writing by
both parties, and that waivers and amendments shall be effective only if made by
non-pre-printed agreements clearly understood by both parties to be an amendment
or waiver. The failure of either party to enforce its rights under this
Agreement at any time for any period shall not be construed as a waiver of such
rights.

        15.2. Governing Law and Legal Actions. This Agreement shall be governed
by and construed under the laws of the State of Arizona without regard to
conflicts of laws provisions thereof and without regard to the United Nations
Convention on Contracts for the International Sale of Goods. Unless otherwise
elected by Ventana in writing for a particular instance (which Ventana may do at
its option), the sole jurisdiction and venue for actions related to the subject
matter hereof initiated by Ventana shall be the Arizona state and U.S. federal
courts having within their jurisdiction the location of Ventana's place of
business in Arizona. The sole jurisdiction and venue for actions related to the
subject matter hereof initiated by AccuMed shall be the Illinois state and U.S.
federal courts having within their jurisdiction the location of AccuMed's place
of business in

                                       20
<PAGE>   21

Illinois. Both parties consent to the jurisdiction of such courts and agree that
process may be served in the manner provided herein for giving of notices or
otherwise as allowed by Arizona or Illinois state, as is applicable, or U.S.
federal law. In any action or proceeding to enforce rights under this Agreement,
the prevailing party shall be entitled to recover costs and attorneys' fees.

        15.3 Headings. Headings and captions are for convenience only and are
not to be used in the interpretation of this Agreement.

        15.4 Notices. Notices under this Agreement shall be sufficient only if
personally delivered, delivered by a major commercial rapid delivery courier
service or mailed by certified or registered mail, return receipt requested to a
party at its addresses first set forth herein or as amended by notice pursuant
to this subsection, to the attention of the Chief Executive Officer in the case
of AccuMed and to the attention of the Chief Financial Officer in the case of
Ventana. Any notice sent by AccuMed hereunder shall further require sending a
copy of such notice to: Ventana Medical Systems, Inc., 3865 N. Business Center
Drive, Tucson, AZ 85705, Attention: Legal Dept. If not received sooner, notice
by mail shall be deemed received 5 days after deposit in the U.S. mails.

        15.5 Entire Agreement. This Agreement supersedes all proposals, oral or
written, all negotiations, conversations, or discussions between or among
parties relating to the subject matter of this Agreement and all past dealing or
industry custom.

        15.6 Severability. If any provision of this Agreement is held to be
illegal or unenforceable, that provision shall be limited or eliminated to the
minimum extent necessary so that this Agreement shall otherwise remain in full
force and effect and enforceable.

        15.7 Basis of Bargain. Each party recognizes and agrees that the
warranty disclaimers and liability and remedy limitations in this Agreement are
material bargained for bases of this Agreement and that they have been taken
into account and reflected in determining the consideration to be given by each
party under this Agreement and in the decision by each party to enter into this
Agreement.

        15.8 Relationship of Parties. The parties hereto expressly understand
and agree that the other is an independent contractor in the performance of each
and every part of this Agreement, is solely responsible for all of its employees
and agents and its labor costs and expenses arising in connection therewith.

        15.9 Assignment. This Agreement and the rights and obligations hereunder
are not transferable or assignable without the prior written consent of the
parties hereto, except for rights to payment and except to a person or entity
who acquires all or substantially all of the assets or business of a party,
whether by sale, merger or otherwise.

        15.10 Publicity and Press Releases. Except to the extent necessary under
applicable laws, the parties agree that no press releases or other publicity
relating to the

                                       21
<PAGE>   22

substance of the matters contained herein will be made without joint approval. A
press release announcing this Agreement will be jointly developed and released
by the parties.

        15.11 Force Majeure. No liability or loss of rights hereunder shall
result to either party from delay or failure in performance (other than payment)
caused by force majeure, that is, circumstances beyond the reasonable control of
the party affected thereby, including, without limitation, acts of God, fire,
flood, war, government action, compliance with laws or regulations (including,
without limitation, those related to infringement), strikes, lockouts or other
serious labor disputes, or shortage of or inability to obtain material or
equipment.

        15.12 Remedies. Except as otherwise expressly stated in this Agreement,
the rights and remedies of a party set forth herein with respect to failure of
the other to comply with the terms of this Agreement (including, without
limitation, rights of full termination of this Agreement) are not exclusive, the
exercise thereof shall not constitute an election of remedies and the aggrieved
party shall in all events be entitled to seek whatever additional remedies may
be available in law or in equity.

        15.13 Nonsolicitation. Neither party will encourage or solicit any
employee or consultant to leave the employ of the other; provided that the
foregoing (i) does not prohibit mass media advertising not specifically directed
towards employees or consultants of a party and (ii) will not apply after any
termination or expiration of this Agreement.

                            [SIGNATURES ON NEXT PAGE]

                                       22
<PAGE>   23

ACCUMED                                      VENTANA

By:     /s/ PAUL LAVALLEE                    By:    /s/  JOHN PATIENCE
        ---------------------------                 ----------------------------
Name:   Paul Lavallee                               Name:  John Patience
Title:  Chairman and CEO                            Title: Vice Chairman

                                       23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]